{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Decorator Endpoint"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "This endpoint takes in a knowledge graph from another reasoner, and augments its edges it with sentences from GNBR."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import requests\n",
    "\n",
    "def pubs(question):\n",
    "    url=f'https://gnbr-reason.ncats.io/decorator'\n",
    "    print(url)\n",
    "    response = requests.post(url,json=question)\n",
    "    print( f\"Return Status: {response.status_code}\" )\n",
    "    if response.status_code == 200:\n",
    "        return response.json()\n",
    "    return {}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Load WF1 module 1 output from rtx\n",
    "\n",
    "Import data and do some massaging to bring up to 0.9 standard"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('wf1mod1_1_ebola_gamma.txt') as f:\n",
    "    rtx = json.load(f)\n",
    "\n",
    "# Specify result number in range 0-4\n",
    "index = 0\n",
    "    \n",
    "rtx_result = rtx['result_list'][index]\n",
    "\n",
    "for edge in rtx_result['result_graph']['edge_list']:\n",
    "    edge['publications'] = list(edge['publications'].split(','))\n",
    "\n",
    "for node in rtx_result['result_graph']['node_list']:\n",
    "    node['type'] = [node['type']]\n",
    "    \n",
    "node_list = rtx_result['result_graph']['node_list']\n",
    "edge_list = rtx_result['result_graph']['edge_list']\n",
    "\n",
    "query_graph = {\n",
    "    'nodes': node_list, \n",
    "    'edges': edge_list\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Construct query object"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "query = {\n",
    "    \"query_message\": {\n",
    "        \"query_graph\": query_graph\n",
    "    }\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Post Query to Endpoint"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://gnbr-reason.ncats.io/decorator\n",
      "Return Status: 200\n"
     ]
    }
   ],
   "source": [
    "KG = pubs(query)['results'][0]['result_graph']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Print results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'edges': [{'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0012243',\n",
      "            'target_id': 'MONDO:0005737',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:20460638',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20460638',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'In the present study , we have used '\n",
      "                                          'a pair of sequence-specific primers '\n",
      "                                          'in reverse transcription-polymerase '\n",
      "                                          'chain reaction -LRB- RT-PCR -RRB- '\n",
      "                                          'and sequence analysis to '\n",
      "                                          'demonstrate that the X-linked gene '\n",
      "                                          'encoding SPAN-Xb is expressed in '\n",
      "                                          'multiple_myeloma and other '\n",
      "                                          'hematologic_malignancies such as '\n",
      "                                          'chronic_lymphocytic_leukemia -LRB- '\n",
      "                                          'CLL -RRB- , '\n",
      "                                          'chronic_myeloid_leukemia -LRB- CML '\n",
      "                                          '-RRB- , and acute_myeloid_leukemia '\n",
      "                                          '-LRB- AML -RRB- .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Gene expression and immunologic '\n",
      "                                          'consequence of SPAN-Xb in myeloma '\n",
      "                                          'and other hematologic_malignancies '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Our results provide the first '\n",
      "                                          'evidence showing the role of '\n",
      "                                          'promoter methylation in the primary '\n",
      "                                          'regulation of SPAN-Xb and the '\n",
      "                                          'ability of IL-7 and GM-CSF to '\n",
      "                                          'further enhance SPAN-Xb gene and '\n",
      "                                          'protein expression in myeloma cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'SPAN-Xb expression in myeloma cells '\n",
      "                                          'is dependent on promoter '\n",
      "                                          'hypomethylation and can be '\n",
      "                                          'upregulated pharmacologically .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'SPAN-Xb is a novel cancer-testis '\n",
      "                                          'antigen in multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'In this study , we determined the '\n",
      "                                          'mechanisms regulating SPAN-Xb '\n",
      "                                          'expression in MM .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Both IL-7 and GM-CSF were also able '\n",
      "                                          'to upregulate the expression of '\n",
      "                                          'SPAN-Xb in myeloma cells , but only '\n",
      "                                          'after the promoter sequence has '\n",
      "                                          'been hypomethylated .'},\n",
      "                                {'name': 'PMID:16187275',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'Tumor cells were treated with '\n",
      "                                          '5-azacytidine and a panel of '\n",
      "                                          'cytokines were used to determine '\n",
      "                                          'their ability to induce SPAN-Xb '\n",
      "                                          'expression .'},\n",
      "                                {'name': 'PMID:16187275',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'name': 'PMID:20108890',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'The type I melanoma antigen gene '\n",
      "                                          '-LRB- MAGE -RRB- proteins CT7 -LRB- '\n",
      "                                          'MAGE-C1 -RRB- and MAGE-A3 are '\n",
      "                                          'commonly expressed in '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- , '\n",
      "                                          'and their expression correlates '\n",
      "                                          'with increased plasma cell '\n",
      "                                          'proliferation and poor clinical '\n",
      "                                          'outcome .'},\n",
      "                                {'name': 'PMID:20108890',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'Cellular immune responses against '\n",
      "                                          'CT7 -LRB- MAGE-C1 -RRB- and humoral '\n",
      "                                          'responses against other '\n",
      "                                          'cancer-testis antigens in '\n",
      "                                          'multiple_myeloma patients .'},\n",
      "                                {'name': 'PMID:20108890',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'CT7 and MAGE-A3 are promising '\n",
      "                                          'antigenic targets for therapeutic '\n",
      "                                          'tumor vaccines in myeloma ; '\n",
      "                                          'therefore , it is critical to '\n",
      "                                          'determine if they are immunogenic '\n",
      "                                          'in MM patients .'},\n",
      "                                {'name': 'PMID:10916472',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10916472',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:20460638',\n",
      "                             'PMID:12393489',\n",
      "                             'PMID:16187275',\n",
      "                             'PMID:20108890',\n",
      "                             'PMID:10916472'],\n",
      "            'source_id': 'HP:0012243',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0000951',\n",
      "            'target_id': 'MONDO:0005737',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18525436',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18525436',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:14535581',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14535581',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19322189',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19322189',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:18525436',\n",
      "                             'PMID:18624684',\n",
      "                             'PMID:14535581',\n",
      "                             'PMID:19322189',\n",
      "                             'PMID:15148528'],\n",
      "            'source_id': 'HP:0000951',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10009889298240793,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0025142',\n",
      "            'target_id': 'MONDO:0005737',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10066567223612977,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0025142',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0011873',\n",
      "            'target_id': 'MONDO:0005737',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10003566602192082,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0011873',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002017',\n",
      "            'target_id': 'MONDO:0005737',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10194641354278611,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002017',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0004364',\n",
      "            'target_id': 'MONDO:0005737',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:2082113',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2082113',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7656787',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7656787',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:184307',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/184307',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:21501555',\n",
      "                             'PMID:2082113',\n",
      "                             'PMID:7656787',\n",
      "                             'PMID:17026821',\n",
      "                             'PMID:184307'],\n",
      "            'source_id': 'HP:0004364',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0010937',\n",
      "            'target_id': 'MONDO:0005737',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0010937',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000168',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0025032',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0410042',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0100022',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000001',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0025031',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000163',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000153',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012253',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001574',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000152',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012252',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000140',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10162161611004383,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002315',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000119',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012649',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001392',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10007832927324634,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012647',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011458',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10007648247155865,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011450',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.100059733423286,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011947',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011446',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011875',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002088',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011355',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002086',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011277',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012638',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011842',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000080',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011123',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0010978',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000079',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011830',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011821',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10270648643912739,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002014',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011122',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10085479920936957,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0003256',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000078',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0031072',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012531',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011121',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0010939',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0031071',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011804',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002012',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000077',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0010935',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10021449945164984,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000988',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0003110',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10063436287712868,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012378',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012374',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000008',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0003011',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0030012',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001999',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012372',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000929',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011024',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0004372',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.2716687576748851,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001945',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0008373',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0010460',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10003818938327114,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001933',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10045947130861621,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001928',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10625770163746451,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0010280',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0009121',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000924',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0100749',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001873',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001324',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.disease_get_phenotype', \"\n",
      "                           \"'biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0100608',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10499540879762137,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002721',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000093',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10057937367603564,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0100806',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10007445873623189,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012211',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002239',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.1000045147796158,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000421',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0000083',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.1009513881430828,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002829',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012719',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001882',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10034140048152596,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001892',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001872',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002795',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0005105',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001626',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002597',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0025015',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011354',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011276',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0030680',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011029',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011028',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.4071474314830641,\n",
      "            'edge_attributes': [{'name': 'PMID:8800793',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8800793',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:8800793'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0011025',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9283226',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9283226',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22253531',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22253531',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:17940942',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17940942',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22761967',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22761967',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:21122234',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21122234',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:9283226',\n",
      "                             'PMID:22253531',\n",
      "                             'PMID:17940942',\n",
      "                             'PMID:22761967',\n",
      "                             'PMID:21122234'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012337',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9283226',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9283226',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22253531',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22253531',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:17940942',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17940942',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22761967',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22761967',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:21122234',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21122234',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:9283226',\n",
      "                             'PMID:22253531',\n",
      "                             'PMID:17940942',\n",
      "                             'PMID:22761967',\n",
      "                             'PMID:21122234'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0004370',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:23233935',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/23233935',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:21329775',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21329775',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10924796',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10924796',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11222689',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11222689',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:23189855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/23189855',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:23233935',\n",
      "                             'PMID:21329775',\n",
      "                             'PMID:10924796',\n",
      "                             'PMID:11222689',\n",
      "                             'PMID:23189855'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0012639',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:23233935',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/23233935',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:21329775',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21329775',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10924796',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10924796',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11222689',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11222689',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:23189855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/23189855',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:23233935',\n",
      "                             'PMID:21329775',\n",
      "                             'PMID:10924796',\n",
      "                             'PMID:11222689',\n",
      "                             'PMID:23189855'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0002011',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:17940972',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17940972',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11798241',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11798241',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15288821',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15288821',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:14639531',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14639531',\n",
      "                                 'value': 'Mechanisms underlying '\n",
      "                                          'coagulation_abnormalities in '\n",
      "                                          'ebola_hemorrhagic_fever : '\n",
      "                                          'overexpression of tissue_factor in '\n",
      "                                          'primate monocytes/macrophages is a '\n",
      "                                          'key event .'},\n",
      "                                {'name': 'PMID:15896665',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15896665',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:17940972',\n",
      "                             'PMID:11798241',\n",
      "                             'PMID:15288821',\n",
      "                             'PMID:14639531',\n",
      "                             'PMID:15896665'],\n",
      "            'source_id': 'MONDO:0005737',\n",
      "            'target_id': 'HP:0001977',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0010939',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18525436',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18525436',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:14535581',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14535581',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19322189',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19322189',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:18525436',\n",
      "                             'PMID:18624684',\n",
      "                             'PMID:14535581',\n",
      "                             'PMID:19322189',\n",
      "                             'PMID:15148528'],\n",
      "            'source_id': 'HP:0011123',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10003915719747636,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0003110',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10002081775056648,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001392',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18922293',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18922293',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15288860',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15288860',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11843289',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11843289',\n",
      "                                 'value': 'To the best of our knowledge , CD55 '\n",
      "                                          '- or CD59-deficient red cells have '\n",
      "                                          'not been detected in '\n",
      "                                          'plasma_cell_dyscrasias -LRB- PCDs '\n",
      "                                          '-RRB- .'},\n",
      "                                {'name': 'PMID:14077037',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14077037',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:1609190',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/1609190',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:18922293',\n",
      "                             'PMID:15288860',\n",
      "                             'PMID:11843289',\n",
      "                             'PMID:14077037',\n",
      "                             'PMID:1609190'],\n",
      "            'source_id': 'HP:0011875',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10030487443690583,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0100749',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10013012171539015,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0000077',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'In this study , we examined MDM2 '\n",
      "                                          'expression and function in '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- '\n",
      "                                          'cells .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'We next studied the association of '\n",
      "                                          'MDM2 with wtp53 and/or mutant p53 '\n",
      "                                          '-LRB- mtp53 -RRB- , E2F-1 , CDK4 , '\n",
      "                                          'and p21 .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'These data suggest that MDM2 may '\n",
      "                                          'enhance cell-cycle progression in '\n",
      "                                          'MM cells both by activating E2F-1 '\n",
      "                                          'and by downregulating cell-cycle '\n",
      "                                          'inhibitory proteins -LRB- wtp53 and '\n",
      "                                          'p21 -RRB- .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'The murine_double_minute_2 -LRB- '\n",
      "                                          'MDM2 -RRB- protein facilitates G1 '\n",
      "                                          'to S phase transition by activation '\n",
      "                                          'of E2F-1 and can enhance cell '\n",
      "                                          'survival by suppressing wild-type '\n",
      "                                          'p53 -LRB- wtp53 -RRB- function .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'The novel , proteasome-independent '\n",
      "                                          'NF-kappaB inhibitor V1810 induces '\n",
      "                                          'apoptosis and cell cycle arrest in '\n",
      "                                          'multiple_myeloma and overcomes '\n",
      "                                          'NF-kappaB-mediated drug resistance '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Taken together , the novel , '\n",
      "                                          'proteasome-independent NF-kappaB '\n",
      "                                          'inhibitor V1810 induces apoptosis '\n",
      "                                          'and cell cycle arrest in '\n",
      "                                          'multiple_myeloma cells at a '\n",
      "                                          'concentration range that can be '\n",
      "                                          'achieved in vivo .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'At this concentration , V1810 '\n",
      "                                          'potently induces apoptosis in all '\n",
      "                                          'four multiple_myeloma cell lines '\n",
      "                                          'assessed -LRB- IC -LRB- 50 -RRB- = '\n",
      "                                          '5-12 micromol/L -RRB- as well as in '\n",
      "                                          'primary multiple_myeloma cells '\n",
      "                                          '-LRB- IC -LRB- 50 -RRB- = 5-40 '\n",
      "                                          'micromol/L -RRB- .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'V1810 and melphalan synergistically '\n",
      "                                          'decrease multiple_myeloma cell '\n",
      "                                          'viability .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Evidence is increasing that '\n",
      "                                          'aberrant NF-kappaB activation is '\n",
      "                                          'crucial for multiple_myeloma '\n",
      "                                          'pathophysiology and a promising '\n",
      "                                          'target for new antimyeloma '\n",
      "                                          'therapies .'},\n",
      "                                {'name': 'PMID:10706856',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10706856',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Therefore , BMP-2 induces apoptosis '\n",
      "                                          'in various human myeloma cells by '\n",
      "                                          'means of the down-regulation of '\n",
      "                                          'Bcl-x -LRB- L -RRB- and by '\n",
      "                                          'cell-cycle arrest through the '\n",
      "                                          'up-regulation of p21 -LRB- '\n",
      "                                          'CIP1/WAF1 -RRB- and p27 -LRB- KIP1 '\n",
      "                                          '-RRB- and by the '\n",
      "                                          'hypophosphorylation of Rb .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Bone_morphogenetic_protein-2 '\n",
      "                                          'induces apoptosis in human myeloma '\n",
      "                                          'cells with modulation of STAT3 .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'We show in this report a novel '\n",
      "                                          'function of BMPs in hematopoietic '\n",
      "                                          'cells : BMP-2 induces apoptosis not '\n",
      "                                          'only in human myeloma cell lines '\n",
      "                                          '-LRB- U266 , RPMI 8226 , HS-Sultan '\n",
      "                                          ', IM-9 , OPM-2 , and KMS-12 cells '\n",
      "                                          '-RRB- , but also in primary samples '\n",
      "                                          'from patients with multiple_myeloma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'We conclude that BMP-2 would be '\n",
      "                                          'useful as a novel therapeutic agent '\n",
      "                                          'in the treatment of '\n",
      "                                          'multiple_myeloma both by means of '\n",
      "                                          'its antitumor effect of inducing '\n",
      "                                          'apoptotis and through its original '\n",
      "                                          'bone-inducing activity , because '\n",
      "                                          'bone_lesions are frequently seen in '\n",
      "                                          'myeloma patients .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'In studies of apoptosis-associated '\n",
      "                                          'proteins , BMP-2 was seen to '\n",
      "                                          'down-regulate the expression of '\n",
      "                                          'Bcl-x -LRB- L -RRB- ; however , '\n",
      "                                          'BMP-2 had no effects on the '\n",
      "                                          'expression of Bcl-2 , Bax , or Bad '\n",
      "                                          '.'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:9292533',\n",
      "                             'PMID:20124446',\n",
      "                             'PMID:10706856',\n",
      "                             'PMID:16772605',\n",
      "                             'PMID:10979940'],\n",
      "            'source_id': 'HP:0012372',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10584276657568648,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001882',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0012638',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:16204017',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16204017',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19805682',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19805682',\n",
      "                                 'value': 'This cohort study aimed to '\n",
      "                                          'calculate the incidence of and '\n",
      "                                          'identify the risk factors for ONJ '\n",
      "                                          'in patients with cancer treated '\n",
      "                                          'with intravenous zoledronate , '\n",
      "                                          'ibandronate , and pamidronate .'},\n",
      "                                {'name': 'PMID:19805682',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19805682',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'},\n",
      "                                {'name': 'PMID:16750501',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16750501',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7387286',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7387286',\n",
      "                                 'value': 'The infection responded to '\n",
      "                                          'treatment with antibiotics , '\n",
      "                                          'including penicillin_G , to which '\n",
      "                                          'the organism was sensitive .'},\n",
      "                                {'name': 'PMID:16243172',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16243172',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:16204017',\n",
      "                             'PMID:19805682',\n",
      "                             'PMID:16750501',\n",
      "                             'PMID:7387286',\n",
      "                             'PMID:16243172'],\n",
      "            'source_id': 'HP:0000168',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:15987304',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15987304',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'Acute_renal_failure from '\n",
      "                                          'multiple_myeloma precipitated by '\n",
      "                                          'ACE inhibitors .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Four patients with '\n",
      "                                          'acute_renal_failure due to myeloma '\n",
      "                                          '-LRB- IgG with lambda , lambda , '\n",
      "                                          'lambda , IgG with kappa -RRB- were '\n",
      "                                          'studied ; serum creatinine was 4.7 '\n",
      "                                          ', 5.9 , 4.25 , 10.8 mg % , and '\n",
      "                                          'proteinuria 2.1 , 2.8 , 5.2 , 4.2 '\n",
      "                                          'g/24h respectively .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'BACKGROUND : Myeloma is the second '\n",
      "                                          'most common haematological '\n",
      "                                          'malignancy and is a cause of severe '\n",
      "                                          'acute_kidney_injury -LRB- serum '\n",
      "                                          'creatinine > or = 500 micromol/L '\n",
      "                                          '-RRB- that has long been associated '\n",
      "                                          'with a poor prognosis , although '\n",
      "                                          'previous series have been small .'},\n",
      "                                {'name': 'PMID:19767634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19767634',\n",
      "                                 'value': 'The advent of efficacious low '\n",
      "                                          'toxicity chemotherapy -LRB- such as '\n",
      "                                          'thalidomide and bortezomib -RRB- '\n",
      "                                          'and new dialysis techniques to '\n",
      "                                          'remove free light chains may '\n",
      "                                          'radically alter the outcome of this '\n",
      "                                          'group of patients .'},\n",
      "                                {'name': 'PMID:19033691',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19033691',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:15987304',\n",
      "                             'PMID:10074605',\n",
      "                             'PMID:7243808',\n",
      "                             'PMID:19767634',\n",
      "                             'PMID:19033691'],\n",
      "            'source_id': 'HP:0000079',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:8209543',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8209543',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8831994',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8831994',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:12111647',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'Extensive evidence has shown that '\n",
      "                                          'epoetin is effective in the '\n",
      "                                          'treatment of '\n",
      "                                          'cancer-associated_anemia .'},\n",
      "                                {'name': 'PMID:12111647',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'An international expert panel met '\n",
      "                                          'to develop treatment '\n",
      "                                          'recommendations for the use of '\n",
      "                                          'epoetin in MM and CLL patients .'},\n",
      "                                {'name': 'PMID:12111647',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'Management of disease-related '\n",
      "                                          'anemia in patients with '\n",
      "                                          'multiple_myeloma or '\n",
      "                                          'chronic_lymphocytic_leukemia : '\n",
      "                                          'epoetin treatment recommendations '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:12111647',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12111647',\n",
      "                                 'value': 'Patients with hemoglobin 10-12 g/dl '\n",
      "                                          'should receive epoetin if they '\n",
      "                                          'suffer from significant symptoms of '\n",
      "                                          'anemia and/or have progressively '\n",
      "                                          'decreasing hemoglobin values .'},\n",
      "                                {'name': 'PMID:845991',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/845991',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:2803933',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2803933',\n",
      "                                 'value': 'We conclude that IL2 may be used in '\n",
      "                                          'minimal residual '\n",
      "                                          'haematological_malignancy , and by '\n",
      "                                          'producing anti-neoplastic effector '\n",
      "                                          'cells has the potential , as yet '\n",
      "                                          'unproven , to prolong disease-free '\n",
      "                                          'survival of patients entering '\n",
      "                                          'remission .'},\n",
      "                                {'name': 'PMID:2803933',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2803933',\n",
      "                                 'value': 'A phase I clinical trial of '\n",
      "                                          'recombinant interleukin_2 following '\n",
      "                                          'high dose chemo-radiotherapy for '\n",
      "                                          'haematological_malignancy : '\n",
      "                                          'applicability to the elimination of '\n",
      "                                          'minimal residual_disease .'},\n",
      "                                {'name': 'PMID:2803933',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2803933',\n",
      "                                 'value': 'Biological response modifiers such '\n",
      "                                          'as interleukin_2 -LRB- IL2 -RRB- '\n",
      "                                          'may be most effective in the '\n",
      "                                          'setting of minimal residual_disease '\n",
      "                                          '.'}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:8209543',\n",
      "                             'PMID:8831994',\n",
      "                             'PMID:12111647',\n",
      "                             'PMID:845991',\n",
      "                             'PMID:2803933'],\n",
      "            'source_id': 'HP:0011446',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:3859250',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3859250',\n",
      "                                 'value': 'Forty-two cases of '\n",
      "                                          'hematological_malignancy -LRB- 18 '\n",
      "                                          'cases of CML , three cases of '\n",
      "                                          'polycythemia vera , 10 cases of '\n",
      "                                          'malignant_lymphoma and 11 cases of '\n",
      "                                          'multiple_myeloma -RRB- were treated '\n",
      "                                          'with MCNU .'},\n",
      "                                {'name': 'PMID:3337064',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3337064',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7865485',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7865485',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:16930333',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16930333',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:3859250',\n",
      "                             'PMID:3337064',\n",
      "                             'PMID:7865485',\n",
      "                             'PMID:16596146',\n",
      "                             'PMID:16930333'],\n",
      "            'source_id': 'HP:0011024',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.1261638138991693,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001873',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0011821',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10038599038053941,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002239',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:3859250',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3859250',\n",
      "                                 'value': 'Forty-two cases of '\n",
      "                                          'hematological_malignancy -LRB- 18 '\n",
      "                                          'cases of CML , three cases of '\n",
      "                                          'polycythemia vera , 10 cases of '\n",
      "                                          'malignant_lymphoma and 11 cases of '\n",
      "                                          'multiple_myeloma -RRB- were treated '\n",
      "                                          'with MCNU .'},\n",
      "                                {'name': 'PMID:3337064',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3337064',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7865485',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7865485',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:16930333',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16930333',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:3859250',\n",
      "                             'PMID:3337064',\n",
      "                             'PMID:7865485',\n",
      "                             'PMID:16596146',\n",
      "                             'PMID:16930333'],\n",
      "            'source_id': 'HP:0025031',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10119954135206011,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0000421',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.1084245639727498,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001945',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:15987304',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15987304',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'Acute_renal_failure from '\n",
      "                                          'multiple_myeloma precipitated by '\n",
      "                                          'ACE inhibitors .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Four patients with '\n",
      "                                          'acute_renal_failure due to myeloma '\n",
      "                                          '-LRB- IgG with lambda , lambda , '\n",
      "                                          'lambda , IgG with kappa -RRB- were '\n",
      "                                          'studied ; serum creatinine was 4.7 '\n",
      "                                          ', 5.9 , 4.25 , 10.8 mg % , and '\n",
      "                                          'proteinuria 2.1 , 2.8 , 5.2 , 4.2 '\n",
      "                                          'g/24h respectively .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'BACKGROUND : Myeloma is the second '\n",
      "                                          'most common haematological '\n",
      "                                          'malignancy and is a cause of severe '\n",
      "                                          'acute_kidney_injury -LRB- serum '\n",
      "                                          'creatinine > or = 500 micromol/L '\n",
      "                                          '-RRB- that has long been associated '\n",
      "                                          'with a poor prognosis , although '\n",
      "                                          'previous series have been small .'},\n",
      "                                {'name': 'PMID:19767634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19767634',\n",
      "                                 'value': 'The advent of efficacious low '\n",
      "                                          'toxicity chemotherapy -LRB- such as '\n",
      "                                          'thalidomide and bortezomib -RRB- '\n",
      "                                          'and new dialysis techniques to '\n",
      "                                          'remove free light chains may '\n",
      "                                          'radically alter the outcome of this '\n",
      "                                          'group of patients .'},\n",
      "                                {'name': 'PMID:19033691',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19033691',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:15987304',\n",
      "                             'PMID:10074605',\n",
      "                             'PMID:7243808',\n",
      "                             'PMID:19767634',\n",
      "                             'PMID:19033691'],\n",
      "            'source_id': 'HP:0000001',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:16862980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16862980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:106626',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/106626',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16651845',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16651845',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:1906116',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/1906116',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:2974181',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2974181',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:16862980',\n",
      "                             'PMID:106626',\n",
      "                             'PMID:16651845',\n",
      "                             'PMID:1906116',\n",
      "                             'PMID:2974181'],\n",
      "            'source_id': 'HP:0009121',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0000152',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10000902964543334,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002011',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18525436',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18525436',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:14535581',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14535581',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19322189',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19322189',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:18525436',\n",
      "                             'PMID:18624684',\n",
      "                             'PMID:14535581',\n",
      "                             'PMID:19322189',\n",
      "                             'PMID:15148528'],\n",
      "            'source_id': 'HP:0011122',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10000515056147641,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0011029',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002088',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.11326772557394615,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0012378',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18525436',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18525436',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:14535581',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14535581',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19322189',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19322189',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:18525436',\n",
      "                             'PMID:18624684',\n",
      "                             'PMID:14535581',\n",
      "                             'PMID:19322189',\n",
      "                             'PMID:15148528'],\n",
      "            'source_id': 'HP:0001574',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:1525326',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/1525326',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:2941196',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2941196',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8681032',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8681032',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8620298',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8620298',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8440074',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440074',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:1525326',\n",
      "                             'PMID:2941196',\n",
      "                             'PMID:8681032',\n",
      "                             'PMID:8620298',\n",
      "                             'PMID:8440074'],\n",
      "            'source_id': 'HP:0012647',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10048473459451068,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0012211',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Even in low TE incidence areas , '\n",
      "                                          'thalidomide combined with '\n",
      "                                          'dexamethasone was more thrombogenic '\n",
      "                                          'compared with others .'},\n",
      "                                {'name': 'PMID:9240635',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9240635',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The potential role of thalidomide '\n",
      "                                          'in the treatment of human neoplasia '\n",
      "                                          'will be confirmed by means of '\n",
      "                                          'randomized clinical trials .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The breakthrough discovery of the '\n",
      "                                          'anti-angiogenic effects of '\n",
      "                                          'thalidomide gave impetus to a '\n",
      "                                          'series of clinical trials in '\n",
      "                                          'patients with solid tumors and '\n",
      "                                          'hematologic_malignancies .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'A randomized phase 3 trial of '\n",
      "                                          'thalidomide and prednisone as '\n",
      "                                          'maintenance therapy after ASCT in '\n",
      "                                          'patients with MM with a '\n",
      "                                          'quality-of-life assessment : the '\n",
      "                                          'National Cancer Institute of Canada '\n",
      "                                          'Clinicals Trials Group Myeloma 10 '\n",
      "                                          'Trial .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide is an antiangiogenic '\n",
      "                                          'drug used in cancer therapy .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has shown clinical '\n",
      "                                          'antitumor activity in single-agent '\n",
      "                                          ', phase II clinical trials in '\n",
      "                                          'AIDS-related Kaposi_sarcoma , '\n",
      "                                          'glioma , multiple_myeloma '\n",
      "                                          'refractory to chemotherapy , and '\n",
      "                                          'hormone-refractory_prostate_cancer '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has been shown to block '\n",
      "                                          'the activity of angiogenic '\n",
      "                                          'substances like bFGF , VEGF and '\n",
      "                                          'interleukin_6 .'}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:11521808',\n",
      "                             'PMID:9240635',\n",
      "                             'PMID:11188934',\n",
      "                             'PMID:23297129',\n",
      "                             'PMID:19399582'],\n",
      "            'source_id': 'HP:0000163',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0005105',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:823190',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/823190',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:2082113',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2082113',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16761740',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16761740',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16966268',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16966268',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:6779622',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/6779622',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:823190',\n",
      "                             'PMID:2082113',\n",
      "                             'PMID:16761740',\n",
      "                             'PMID:16966268',\n",
      "                             'PMID:6779622'],\n",
      "            'source_id': 'HP:0410042',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0010978',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002315',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.14816734668104659,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0000083',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:15987304',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15987304',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'Acute_renal_failure from '\n",
      "                                          'multiple_myeloma precipitated by '\n",
      "                                          'ACE inhibitors .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Four patients with '\n",
      "                                          'acute_renal_failure due to myeloma '\n",
      "                                          '-LRB- IgG with lambda , lambda , '\n",
      "                                          'lambda , IgG with kappa -RRB- were '\n",
      "                                          'studied ; serum creatinine was 4.7 '\n",
      "                                          ', 5.9 , 4.25 , 10.8 mg % , and '\n",
      "                                          'proteinuria 2.1 , 2.8 , 5.2 , 4.2 '\n",
      "                                          'g/24h respectively .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'BACKGROUND : Myeloma is the second '\n",
      "                                          'most common haematological '\n",
      "                                          'malignancy and is a cause of severe '\n",
      "                                          'acute_kidney_injury -LRB- serum '\n",
      "                                          'creatinine > or = 500 micromol/L '\n",
      "                                          '-RRB- that has long been associated '\n",
      "                                          'with a poor prognosis , although '\n",
      "                                          'previous series have been small .'},\n",
      "                                {'name': 'PMID:19767634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19767634',\n",
      "                                 'value': 'The advent of efficacious low '\n",
      "                                          'toxicity chemotherapy -LRB- such as '\n",
      "                                          'thalidomide and bortezomib -RRB- '\n",
      "                                          'and new dialysis techniques to '\n",
      "                                          'remove free light chains may '\n",
      "                                          'radically alter the outcome of this '\n",
      "                                          'group of patients .'},\n",
      "                                {'name': 'PMID:19033691',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19033691',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:15987304',\n",
      "                             'PMID:10074605',\n",
      "                             'PMID:7243808',\n",
      "                             'PMID:19767634',\n",
      "                             'PMID:19033691'],\n",
      "            'source_id': 'HP:0000119',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10180515084926944,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002721',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.1000638540319212,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0004372',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:19830855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19830855',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Cancer cells were treated with '\n",
      "                                          'TIR-203 at various concentrations '\n",
      "                                          '-LRB- 0-10 M -RRB- and the cell '\n",
      "                                          'viability was measured using the '\n",
      "                                          'MTS assay .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In MM cells , TIR-203 effectively '\n",
      "                                          'inhibited the chymotrypsin-like '\n",
      "                                          '-LRB- CT-L -RRB- , caspase-like '\n",
      "                                          '-LRB- C-L -RRB- , and trypsin-like '\n",
      "                                          '-LRB- T-L -RRB- activities of the '\n",
      "                                          'proteasome .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'RESULTS : TIR-203 inhibited the '\n",
      "                                          'cell proliferation of MM and NB '\n",
      "                                          'cells in a dose-dependent manner at '\n",
      "                                          'significantly lower concentrations '\n",
      "                                          'than SylA .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'MATERIALS AND METHODS : TIR-203 was '\n",
      "                                          'tested against human MM and '\n",
      "                                          'neuroblastoma -LRB- NB -RRB- cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In NB cells , TIR-203 inhibited the '\n",
      "                                          'CT-L and C-L activities , but not '\n",
      "                                          'the T-L activity .'},\n",
      "                                {'name': 'PMID:20022634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20022634',\n",
      "                                 'value': 'Recently , many reports have '\n",
      "                                          'revealed that the PIK3CA gene which '\n",
      "                                          'encodes the p110 catalytic subunit '\n",
      "                                          'of PI3K kinase is mutated in many '\n",
      "                                          'human malignancies .'},\n",
      "                                {'name': 'PMID:15459912',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15459912',\n",
      "                                 'value': 'Proteins exhibiting a significant '\n",
      "                                          'increase in abundance with '\n",
      "                                          'increasing qMab included molecular '\n",
      "                                          'chaperones known to interact '\n",
      "                                          'directly with nascent '\n",
      "                                          'immunoglobulins during their '\n",
      "                                          'folding and assembly -LRB- e.g. , '\n",
      "                                          'BiP , endoplasmin , '\n",
      "                                          'protein_disulfide_isomerase -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17516591',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17516591',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:19830855',\n",
      "                             'PMID:22196580',\n",
      "                             'PMID:20022634',\n",
      "                             'PMID:15459912',\n",
      "                             'PMID:17516591'],\n",
      "            'source_id': 'HP:0010460',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0011458',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0003011',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0001999',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002086',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.disease_get_phenotype', \"\n",
      "                           \"'biolink.phenotype_get_disease']\",\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0012719',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0012253',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:10586130',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10586130',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:4011023',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4011023',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:17179619',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17179619',\n",
      "                                 'value': 'We report two male patients who '\n",
      "                                          'presented with symmetrical , '\n",
      "                                          'painful purpura that evolved into '\n",
      "                                          'bullae and necrotic ulcers , '\n",
      "                                          'predominantly on the extremities , '\n",
      "                                          'over two months in spite of '\n",
      "                                          'conventional therapy including oral '\n",
      "                                          'steroids .'},\n",
      "                                {'name': 'PMID:17042766',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17042766',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:18565291',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18565291',\n",
      "                                 'value': 'New signal transduction inhibitors '\n",
      "                                          ', dasatinib and nilotinib , are '\n",
      "                                          'being used in patients with '\n",
      "                                          'chronic_myelogeneous_leukaemia who '\n",
      "                                          'develop resistance to imatinib .'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:10586130',\n",
      "                             'PMID:4011023',\n",
      "                             'PMID:17179619',\n",
      "                             'PMID:17042766',\n",
      "                             'PMID:18565291'],\n",
      "            'source_id': 'HP:0001933',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:3859250',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3859250',\n",
      "                                 'value': 'Forty-two cases of '\n",
      "                                          'hematological_malignancy -LRB- 18 '\n",
      "                                          'cases of CML , three cases of '\n",
      "                                          'polycythemia vera , 10 cases of '\n",
      "                                          'malignant_lymphoma and 11 cases of '\n",
      "                                          'multiple_myeloma -RRB- were treated '\n",
      "                                          'with MCNU .'},\n",
      "                                {'name': 'PMID:3337064',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3337064',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7865485',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7865485',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:16930333',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16930333',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:3859250',\n",
      "                             'PMID:3337064',\n",
      "                             'PMID:7865485',\n",
      "                             'PMID:16596146',\n",
      "                             'PMID:16930333'],\n",
      "            'source_id': 'HP:0025032',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.102668090780905,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0010280',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:2917910',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2917910',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8938892',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8938892',\n",
      "                                 'value': 'Silver_nitrate cautery is '\n",
      "                                          'frequently used to control '\n",
      "                                          'epistaxis .'},\n",
      "                                {'name': 'PMID:8288980',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8288980',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10493038',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10493038',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15979285',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15979285',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:2917910',\n",
      "                             'PMID:8938892',\n",
      "                             'PMID:8288980',\n",
      "                             'PMID:10493038',\n",
      "                             'PMID:15979285'],\n",
      "            'source_id': 'HP:0012252',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10001297338078918,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001872',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9669141',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9669141',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:2081514',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2081514',\n",
      "                                 'value': 'Interestingly , in sarcoidosis '\n",
      "                                          'there are calcium_oxalate crystals '\n",
      "                                          'in variously distributed '\n",
      "                                          'sarcoid_granuloma , and the '\n",
      "                                          'renal_calculi are composed of '\n",
      "                                          'calcium_oxalate .'},\n",
      "                                {'name': 'PMID:22268507',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22268507',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:576568',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/576568',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:17179397',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17179397',\n",
      "                                 'value': 'PURPOSE : To prospectively assess '\n",
      "                                          'molecular imaging of '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- by '\n",
      "                                          'using the '\n",
      "                                          'radiolabeled_amino_acid_carbon_11 '\n",
      "                                          '-LRB- -LRB- 11 -RRB- C -RRB- '\n",
      "                                          'methionine and positron emission '\n",
      "                                          'tomography -LRB- PET -RRB- / '\n",
      "                                          'computed tomography -LRB- CT -RRB- '\n",
      "                                          '.'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:9669141',\n",
      "                             'PMID:2081514',\n",
      "                             'PMID:22268507',\n",
      "                             'PMID:576568',\n",
      "                             'PMID:17179397'],\n",
      "            'source_id': 'HP:0031071',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:11563589',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11563589',\n",
      "                                 'value': 'The survival time of myeloma '\n",
      "                                          'patients improved from a few months '\n",
      "                                          'to many years after treatment with '\n",
      "                                          'melphalan .'},\n",
      "                                {'name': 'PMID:10067092',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10067092',\n",
      "                                 'value': 'Four courses of chemotherapy -LRB- '\n",
      "                                          'cyclophosphamide , doxorubicin , '\n",
      "                                          'and prednisolone -RRB- and the '\n",
      "                                          'intrathecal administration of '\n",
      "                                          'methotrexate and cytarabine at '\n",
      "                                          '3-week intervals were effective in '\n",
      "                                          'decreasing the pleural_effusions '\n",
      "                                          'and eliminating plasma cells from '\n",
      "                                          'CSF .'},\n",
      "                                {'name': 'PMID:10067092',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10067092',\n",
      "                                 'value': 'A chest radiograph disclosed '\n",
      "                                          'pleural_effusion in both lungs '\n",
      "                                          'containing M-protein and numerous '\n",
      "                                          'abnormal cells .'},\n",
      "                                {'name': 'PMID:6721286',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/6721286',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:4079014',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'One hundred and nine patients with '\n",
      "                                          'infection accompanying '\n",
      "                                          'hematologic_disorders including '\n",
      "                                          'leukemia and lymphoma were treated '\n",
      "                                          'with aztreonam -LRB- AZT -RRB- .'},\n",
      "                                {'name': 'PMID:4079014',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4079014',\n",
      "                                 'value': 'These results indicate that AZT is '\n",
      "                                          'an effective and safe antibiotic '\n",
      "                                          'for the treatment of infections '\n",
      "                                          'accompanying hematologic_disorders '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17917096',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17917096',\n",
      "                                 'value': 'The SLE was treated successfully '\n",
      "                                          'with methylprednisolone and '\n",
      "                                          'chloroquine , and low dose '\n",
      "                                          'maintenance steroid was continued '\n",
      "                                          'with bisphosphonate protection '\n",
      "                                          'until December 1994 when she '\n",
      "                                          'suffered multiple '\n",
      "                                          'vertebral_fractures .'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:11563589',\n",
      "                             'PMID:10067092',\n",
      "                             'PMID:6721286',\n",
      "                             'PMID:4079014',\n",
      "                             'PMID:17917096'],\n",
      "            'source_id': 'HP:0002795',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10056727285268141,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002829',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:15987304',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15987304',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'Acute_renal_failure from '\n",
      "                                          'multiple_myeloma precipitated by '\n",
      "                                          'ACE inhibitors .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Four patients with '\n",
      "                                          'acute_renal_failure due to myeloma '\n",
      "                                          '-LRB- IgG with lambda , lambda , '\n",
      "                                          'lambda , IgG with kappa -RRB- were '\n",
      "                                          'studied ; serum creatinine was 4.7 '\n",
      "                                          ', 5.9 , 4.25 , 10.8 mg % , and '\n",
      "                                          'proteinuria 2.1 , 2.8 , 5.2 , 4.2 '\n",
      "                                          'g/24h respectively .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'BACKGROUND : Myeloma is the second '\n",
      "                                          'most common haematological '\n",
      "                                          'malignancy and is a cause of severe '\n",
      "                                          'acute_kidney_injury -LRB- serum '\n",
      "                                          'creatinine > or = 500 micromol/L '\n",
      "                                          '-RRB- that has long been associated '\n",
      "                                          'with a poor prognosis , although '\n",
      "                                          'previous series have been small .'},\n",
      "                                {'name': 'PMID:19767634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19767634',\n",
      "                                 'value': 'The advent of efficacious low '\n",
      "                                          'toxicity chemotherapy -LRB- such as '\n",
      "                                          'thalidomide and bortezomib -RRB- '\n",
      "                                          'and new dialysis techniques to '\n",
      "                                          'remove free light chains may '\n",
      "                                          'radically alter the outcome of this '\n",
      "                                          'group of patients .'},\n",
      "                                {'name': 'PMID:19033691',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19033691',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:15987304',\n",
      "                             'PMID:10074605',\n",
      "                             'PMID:7243808',\n",
      "                             'PMID:19767634',\n",
      "                             'PMID:19033691'],\n",
      "            'source_id': 'HP:0010935',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:194331',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/194331',\n",
      "                                 'value': 'Finally , the iatrogenic '\n",
      "                                          'manifestations of the locomotor '\n",
      "                                          'system appear mainly due to '\n",
      "                                          'hypolipemic drugs , e.g. the '\n",
      "                                          'muscle_disorders seen in a few '\n",
      "                                          'patients treated with clofibrate .'},\n",
      "                                {'name': 'PMID:21635833',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21635833',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:172108',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/172108',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18705423',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18705423',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7888370',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7888370',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:194331',\n",
      "                             'PMID:21635833',\n",
      "                             'PMID:172108',\n",
      "                             'PMID:18705423',\n",
      "                             'PMID:7888370'],\n",
      "            'source_id': 'HP:0011355',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0011947',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0011450',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10013960392040577,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001324',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001626',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:19830855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19830855',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Cancer cells were treated with '\n",
      "                                          'TIR-203 at various concentrations '\n",
      "                                          '-LRB- 0-10 M -RRB- and the cell '\n",
      "                                          'viability was measured using the '\n",
      "                                          'MTS assay .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In MM cells , TIR-203 effectively '\n",
      "                                          'inhibited the chymotrypsin-like '\n",
      "                                          '-LRB- CT-L -RRB- , caspase-like '\n",
      "                                          '-LRB- C-L -RRB- , and trypsin-like '\n",
      "                                          '-LRB- T-L -RRB- activities of the '\n",
      "                                          'proteasome .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'RESULTS : TIR-203 inhibited the '\n",
      "                                          'cell proliferation of MM and NB '\n",
      "                                          'cells in a dose-dependent manner at '\n",
      "                                          'significantly lower concentrations '\n",
      "                                          'than SylA .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'MATERIALS AND METHODS : TIR-203 was '\n",
      "                                          'tested against human MM and '\n",
      "                                          'neuroblastoma -LRB- NB -RRB- cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In NB cells , TIR-203 inhibited the '\n",
      "                                          'CT-L and C-L activities , but not '\n",
      "                                          'the T-L activity .'},\n",
      "                                {'name': 'PMID:20022634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20022634',\n",
      "                                 'value': 'Recently , many reports have '\n",
      "                                          'revealed that the PIK3CA gene which '\n",
      "                                          'encodes the p110 catalytic subunit '\n",
      "                                          'of PI3K kinase is mutated in many '\n",
      "                                          'human malignancies .'},\n",
      "                                {'name': 'PMID:15459912',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15459912',\n",
      "                                 'value': 'Proteins exhibiting a significant '\n",
      "                                          'increase in abundance with '\n",
      "                                          'increasing qMab included molecular '\n",
      "                                          'chaperones known to interact '\n",
      "                                          'directly with nascent '\n",
      "                                          'immunoglobulins during their '\n",
      "                                          'folding and assembly -LRB- e.g. , '\n",
      "                                          'BiP , endoplasmin , '\n",
      "                                          'protein_disulfide_isomerase -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17516591',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17516591',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:19830855',\n",
      "                             'PMID:22196580',\n",
      "                             'PMID:20022634',\n",
      "                             'PMID:15459912',\n",
      "                             'PMID:17516591'],\n",
      "            'source_id': 'HP:0000140',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9669141',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9669141',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:2081514',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2081514',\n",
      "                                 'value': 'Interestingly , in sarcoidosis '\n",
      "                                          'there are calcium_oxalate crystals '\n",
      "                                          'in variously distributed '\n",
      "                                          'sarcoid_granuloma , and the '\n",
      "                                          'renal_calculi are composed of '\n",
      "                                          'calcium_oxalate .'},\n",
      "                                {'name': 'PMID:22268507',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22268507',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:576568',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/576568',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:17179397',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17179397',\n",
      "                                 'value': 'PURPOSE : To prospectively assess '\n",
      "                                          'molecular imaging of '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- by '\n",
      "                                          'using the '\n",
      "                                          'radiolabeled_amino_acid_carbon_11 '\n",
      "                                          '-LRB- -LRB- 11 -RRB- C -RRB- '\n",
      "                                          'methionine and positron emission '\n",
      "                                          'tomography -LRB- PET -RRB- / '\n",
      "                                          'computed tomography -LRB- CT -RRB- '\n",
      "                                          '.'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:9669141',\n",
      "                             'PMID:2081514',\n",
      "                             'PMID:22268507',\n",
      "                             'PMID:576568',\n",
      "                             'PMID:17179397'],\n",
      "            'source_id': 'HP:0031072',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.10323083204857131,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0002014',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.25832639515782074,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0011804',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:15987304',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15987304',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'We report two cases of '\n",
      "                                          'acute_renal_failure that developed '\n",
      "                                          'suddenly after initiation of '\n",
      "                                          'angiotensin-converting_enzyme -LRB- '\n",
      "                                          'ACE -RRB- inhibitor , both with '\n",
      "                                          'biopsy-proven cast nephropathy .'},\n",
      "                                {'name': 'PMID:10074605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10074605',\n",
      "                                 'value': 'Acute_renal_failure from '\n",
      "                                          'multiple_myeloma precipitated by '\n",
      "                                          'ACE inhibitors .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Steroid pulses and plasmapheresis '\n",
      "                                          'in the treatment of '\n",
      "                                          'acute_renal_failure in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'Four patients with '\n",
      "                                          'acute_renal_failure due to myeloma '\n",
      "                                          '-LRB- IgG with lambda , lambda , '\n",
      "                                          'lambda , IgG with kappa -RRB- were '\n",
      "                                          'studied ; serum creatinine was 4.7 '\n",
      "                                          ', 5.9 , 4.25 , 10.8 mg % , and '\n",
      "                                          'proteinuria 2.1 , 2.8 , 5.2 , 4.2 '\n",
      "                                          'g/24h respectively .'},\n",
      "                                {'name': 'PMID:7243808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7243808',\n",
      "                                 'value': 'BACKGROUND : Myeloma is the second '\n",
      "                                          'most common haematological '\n",
      "                                          'malignancy and is a cause of severe '\n",
      "                                          'acute_kidney_injury -LRB- serum '\n",
      "                                          'creatinine > or = 500 micromol/L '\n",
      "                                          '-RRB- that has long been associated '\n",
      "                                          'with a poor prognosis , although '\n",
      "                                          'previous series have been small .'},\n",
      "                                {'name': 'PMID:19767634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19767634',\n",
      "                                 'value': 'The advent of efficacious low '\n",
      "                                          'toxicity chemotherapy -LRB- such as '\n",
      "                                          'thalidomide and bortezomib -RRB- '\n",
      "                                          'and new dialysis techniques to '\n",
      "                                          'remove free light chains may '\n",
      "                                          'radically alter the outcome of this '\n",
      "                                          'group of patients .'},\n",
      "                                {'name': 'PMID:19033691',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19033691',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:15987304',\n",
      "                             'PMID:10074605',\n",
      "                             'PMID:7243808',\n",
      "                             'PMID:19767634',\n",
      "                             'PMID:19033691'],\n",
      "            'source_id': 'HP:0011277',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'MDM2 constitutively binds to E2F-1 '\n",
      "                                          'in all MM cells , to both wtp53 and '\n",
      "                                          'mtp53 , and to p21 in tumor cells '\n",
      "                                          'lacking p53 .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'In this study , we examined MDM2 '\n",
      "                                          'expression and function in '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- '\n",
      "                                          'cells .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'We next studied the association of '\n",
      "                                          'MDM2 with wtp53 and/or mutant p53 '\n",
      "                                          '-LRB- mtp53 -RRB- , E2F-1 , CDK4 , '\n",
      "                                          'and p21 .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'Treatment of MM cells with MDM2 '\n",
      "                                          'antisense , but not sense , '\n",
      "                                          'nonsense , or scrambled , '\n",
      "                                          'oligodeoxyribonucleotides -LRB- '\n",
      "                                          'ODNs -RRB- decreased DNA synthesis '\n",
      "                                          'and cell viability ; it also '\n",
      "                                          'induced G1 growth_arrest , as '\n",
      "                                          'evidenced by propidium_iodide -LRB- '\n",
      "                                          'PI -RRB- staining and induction of '\n",
      "                                          'retinoblastoma protein -LRB- pRB '\n",
      "                                          '-RRB- to E2F-1 binding .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'These data suggest that MDM2 may '\n",
      "                                          'enhance cell-cycle progression in '\n",
      "                                          'MM cells both by activating E2F-1 '\n",
      "                                          'and by downregulating cell-cycle '\n",
      "                                          'inhibitory proteins -LRB- wtp53 and '\n",
      "                                          'p21 -RRB- .'},\n",
      "                                {'name': 'PMID:9292533',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9292533',\n",
      "                                 'value': 'The murine_double_minute_2 -LRB- '\n",
      "                                          'MDM2 -RRB- protein facilitates G1 '\n",
      "                                          'to S phase transition by activation '\n",
      "                                          'of E2F-1 and can enhance cell '\n",
      "                                          'survival by suppressing wild-type '\n",
      "                                          'p53 -LRB- wtp53 -RRB- function .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'The novel , proteasome-independent '\n",
      "                                          'NF-kappaB inhibitor V1810 induces '\n",
      "                                          'apoptosis and cell cycle arrest in '\n",
      "                                          'multiple_myeloma and overcomes '\n",
      "                                          'NF-kappaB-mediated drug resistance '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Taken together , the novel , '\n",
      "                                          'proteasome-independent NF-kappaB '\n",
      "                                          'inhibitor V1810 induces apoptosis '\n",
      "                                          'and cell cycle arrest in '\n",
      "                                          'multiple_myeloma cells at a '\n",
      "                                          'concentration range that can be '\n",
      "                                          'achieved in vivo .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'At this concentration , V1810 '\n",
      "                                          'potently induces apoptosis in all '\n",
      "                                          'four multiple_myeloma cell lines '\n",
      "                                          'assessed -LRB- IC -LRB- 50 -RRB- = '\n",
      "                                          '5-12 micromol/L -RRB- as well as in '\n",
      "                                          'primary multiple_myeloma cells '\n",
      "                                          '-LRB- IC -LRB- 50 -RRB- = 5-40 '\n",
      "                                          'micromol/L -RRB- .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'V1810 and melphalan synergistically '\n",
      "                                          'decrease multiple_myeloma cell '\n",
      "                                          'viability .'},\n",
      "                                {'name': 'PMID:20124446',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20124446',\n",
      "                                 'value': 'Evidence is increasing that '\n",
      "                                          'aberrant NF-kappaB activation is '\n",
      "                                          'crucial for multiple_myeloma '\n",
      "                                          'pathophysiology and a promising '\n",
      "                                          'target for new antimyeloma '\n",
      "                                          'therapies .'},\n",
      "                                {'name': 'PMID:10706856',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10706856',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:16772605',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16772605',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Therefore , BMP-2 induces apoptosis '\n",
      "                                          'in various human myeloma cells by '\n",
      "                                          'means of the down-regulation of '\n",
      "                                          'Bcl-x -LRB- L -RRB- and by '\n",
      "                                          'cell-cycle arrest through the '\n",
      "                                          'up-regulation of p21 -LRB- '\n",
      "                                          'CIP1/WAF1 -RRB- and p27 -LRB- KIP1 '\n",
      "                                          '-RRB- and by the '\n",
      "                                          'hypophosphorylation of Rb .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'Bone_morphogenetic_protein-2 '\n",
      "                                          'induces apoptosis in human myeloma '\n",
      "                                          'cells with modulation of STAT3 .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'We show in this report a novel '\n",
      "                                          'function of BMPs in hematopoietic '\n",
      "                                          'cells : BMP-2 induces apoptosis not '\n",
      "                                          'only in human myeloma cell lines '\n",
      "                                          '-LRB- U266 , RPMI 8226 , HS-Sultan '\n",
      "                                          ', IM-9 , OPM-2 , and KMS-12 cells '\n",
      "                                          '-RRB- , but also in primary samples '\n",
      "                                          'from patients with multiple_myeloma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'We conclude that BMP-2 would be '\n",
      "                                          'useful as a novel therapeutic agent '\n",
      "                                          'in the treatment of '\n",
      "                                          'multiple_myeloma both by means of '\n",
      "                                          'its antitumor effect of inducing '\n",
      "                                          'apoptotis and through its original '\n",
      "                                          'bone-inducing activity , because '\n",
      "                                          'bone_lesions are frequently seen in '\n",
      "                                          'myeloma patients .'},\n",
      "                                {'name': 'PMID:10979940',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10979940',\n",
      "                                 'value': 'In studies of apoptosis-associated '\n",
      "                                          'proteins , BMP-2 was seen to '\n",
      "                                          'down-regulate the expression of '\n",
      "                                          'Bcl-x -LRB- L -RRB- ; however , '\n",
      "                                          'BMP-2 had no effects on the '\n",
      "                                          'expression of Bcl-2 , Bax , or Bad '\n",
      "                                          '.'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:9292533',\n",
      "                             'PMID:20124446',\n",
      "                             'PMID:10706856',\n",
      "                             'PMID:16772605',\n",
      "                             'PMID:10979940'],\n",
      "            'source_id': 'HP:0012374',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0100608',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.1106241450267268,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0012531',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10202707654549958,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0001892',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:19830855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19830855',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Cancer cells were treated with '\n",
      "                                          'TIR-203 at various concentrations '\n",
      "                                          '-LRB- 0-10 M -RRB- and the cell '\n",
      "                                          'viability was measured using the '\n",
      "                                          'MTS assay .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In MM cells , TIR-203 effectively '\n",
      "                                          'inhibited the chymotrypsin-like '\n",
      "                                          '-LRB- CT-L -RRB- , caspase-like '\n",
      "                                          '-LRB- C-L -RRB- , and trypsin-like '\n",
      "                                          '-LRB- T-L -RRB- activities of the '\n",
      "                                          'proteasome .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'RESULTS : TIR-203 inhibited the '\n",
      "                                          'cell proliferation of MM and NB '\n",
      "                                          'cells in a dose-dependent manner at '\n",
      "                                          'significantly lower concentrations '\n",
      "                                          'than SylA .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'MATERIALS AND METHODS : TIR-203 was '\n",
      "                                          'tested against human MM and '\n",
      "                                          'neuroblastoma -LRB- NB -RRB- cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In NB cells , TIR-203 inhibited the '\n",
      "                                          'CT-L and C-L activities , but not '\n",
      "                                          'the T-L activity .'},\n",
      "                                {'name': 'PMID:20022634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20022634',\n",
      "                                 'value': 'Recently , many reports have '\n",
      "                                          'revealed that the PIK3CA gene which '\n",
      "                                          'encodes the p110 catalytic subunit '\n",
      "                                          'of PI3K kinase is mutated in many '\n",
      "                                          'human malignancies .'},\n",
      "                                {'name': 'PMID:15459912',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15459912',\n",
      "                                 'value': 'Proteins exhibiting a significant '\n",
      "                                          'increase in abundance with '\n",
      "                                          'increasing qMab included molecular '\n",
      "                                          'chaperones known to interact '\n",
      "                                          'directly with nascent '\n",
      "                                          'immunoglobulins during their '\n",
      "                                          'folding and assembly -LRB- e.g. , '\n",
      "                                          'BiP , endoplasmin , '\n",
      "                                          'protein_disulfide_isomerase -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17516591',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17516591',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:19830855',\n",
      "                             'PMID:22196580',\n",
      "                             'PMID:20022634',\n",
      "                             'PMID:15459912',\n",
      "                             'PMID:17516591'],\n",
      "            'source_id': 'HP:0030012',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:19830855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19830855',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Cancer cells were treated with '\n",
      "                                          'TIR-203 at various concentrations '\n",
      "                                          '-LRB- 0-10 M -RRB- and the cell '\n",
      "                                          'viability was measured using the '\n",
      "                                          'MTS assay .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In MM cells , TIR-203 effectively '\n",
      "                                          'inhibited the chymotrypsin-like '\n",
      "                                          '-LRB- CT-L -RRB- , caspase-like '\n",
      "                                          '-LRB- C-L -RRB- , and trypsin-like '\n",
      "                                          '-LRB- T-L -RRB- activities of the '\n",
      "                                          'proteasome .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'RESULTS : TIR-203 inhibited the '\n",
      "                                          'cell proliferation of MM and NB '\n",
      "                                          'cells in a dose-dependent manner at '\n",
      "                                          'significantly lower concentrations '\n",
      "                                          'than SylA .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'MATERIALS AND METHODS : TIR-203 was '\n",
      "                                          'tested against human MM and '\n",
      "                                          'neuroblastoma -LRB- NB -RRB- cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In NB cells , TIR-203 inhibited the '\n",
      "                                          'CT-L and C-L activities , but not '\n",
      "                                          'the T-L activity .'},\n",
      "                                {'name': 'PMID:20022634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20022634',\n",
      "                                 'value': 'Recently , many reports have '\n",
      "                                          'revealed that the PIK3CA gene which '\n",
      "                                          'encodes the p110 catalytic subunit '\n",
      "                                          'of PI3K kinase is mutated in many '\n",
      "                                          'human malignancies .'},\n",
      "                                {'name': 'PMID:15459912',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15459912',\n",
      "                                 'value': 'Proteins exhibiting a significant '\n",
      "                                          'increase in abundance with '\n",
      "                                          'increasing qMab included molecular '\n",
      "                                          'chaperones known to interact '\n",
      "                                          'directly with nascent '\n",
      "                                          'immunoglobulins during their '\n",
      "                                          'folding and assembly -LRB- e.g. , '\n",
      "                                          'BiP , endoplasmin , '\n",
      "                                          'protein_disulfide_isomerase -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17516591',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17516591',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:19830855',\n",
      "                             'PMID:22196580',\n",
      "                             'PMID:20022634',\n",
      "                             'PMID:15459912',\n",
      "                             'PMID:17516591'],\n",
      "            'source_id': 'HP:0000080',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0003256',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10114316542739699,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0000988',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10317368093515289,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'HP:0100806',\n",
      "            'target_id': 'MONDO:0009693',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.09999999999999998,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0100022',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10003887704141323,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0000929',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10034950544697208,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0001928',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.10017018403135936,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0000924',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.1400287582194264,\n",
      "            'edge_attributes': [{'name': '',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': '',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'omnicorp.term_to_term',\n",
      "            'publications': [''],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0000093',\n",
      "            'type': 'literature_co-occurrence'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:3859250',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3859250',\n",
      "                                 'value': 'Forty-two cases of '\n",
      "                                          'hematological_malignancy -LRB- 18 '\n",
      "                                          'cases of CML , three cases of '\n",
      "                                          'polycythemia vera , 10 cases of '\n",
      "                                          'malignant_lymphoma and 11 cases of '\n",
      "                                          'multiple_myeloma -RRB- were treated '\n",
      "                                          'with MCNU .'},\n",
      "                                {'name': 'PMID:3337064',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3337064',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7865485',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7865485',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:16930333',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16930333',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:3859250',\n",
      "                             'PMID:3337064',\n",
      "                             'PMID:7865485',\n",
      "                             'PMID:16596146',\n",
      "                             'PMID:16930333'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0002012',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:3859250',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3859250',\n",
      "                                 'value': 'Forty-two cases of '\n",
      "                                          'hematological_malignancy -LRB- 18 '\n",
      "                                          'cases of CML , three cases of '\n",
      "                                          'polycythemia vera , 10 cases of '\n",
      "                                          'malignant_lymphoma and 11 cases of '\n",
      "                                          'multiple_myeloma -RRB- were treated '\n",
      "                                          'with MCNU .'},\n",
      "                                {'name': 'PMID:3337064',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3337064',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7865485',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7865485',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:16930333',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16930333',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:3859250',\n",
      "                             'PMID:3337064',\n",
      "                             'PMID:7865485',\n",
      "                             'PMID:16596146',\n",
      "                             'PMID:16930333'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0011028',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:3859250',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3859250',\n",
      "                                 'value': 'Forty-two cases of '\n",
      "                                          'hematological_malignancy -LRB- 18 '\n",
      "                                          'cases of CML , three cases of '\n",
      "                                          'polycythemia vera , 10 cases of '\n",
      "                                          'malignant_lymphoma and 11 cases of '\n",
      "                                          'multiple_myeloma -RRB- were treated '\n",
      "                                          'with MCNU .'},\n",
      "                                {'name': 'PMID:3337064',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3337064',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7865485',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7865485',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:16596146',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16596146',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:16930333',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16930333',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:3859250',\n",
      "                             'PMID:3337064',\n",
      "                             'PMID:7865485',\n",
      "                             'PMID:16596146',\n",
      "                             'PMID:16930333'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0011025',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:21501555',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21501555',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:2082113',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2082113',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7656787',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7656787',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:184307',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/184307',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:21501555',\n",
      "                             'PMID:2082113',\n",
      "                             'PMID:7656787',\n",
      "                             'PMID:17026821',\n",
      "                             'PMID:184307'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0012337',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Even in low TE incidence areas , '\n",
      "                                          'thalidomide combined with '\n",
      "                                          'dexamethasone was more thrombogenic '\n",
      "                                          'compared with others .'},\n",
      "                                {'name': 'PMID:9240635',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9240635',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The potential role of thalidomide '\n",
      "                                          'in the treatment of human neoplasia '\n",
      "                                          'will be confirmed by means of '\n",
      "                                          'randomized clinical trials .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The breakthrough discovery of the '\n",
      "                                          'anti-angiogenic effects of '\n",
      "                                          'thalidomide gave impetus to a '\n",
      "                                          'series of clinical trials in '\n",
      "                                          'patients with solid tumors and '\n",
      "                                          'hematologic_malignancies .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'A randomized phase 3 trial of '\n",
      "                                          'thalidomide and prednisone as '\n",
      "                                          'maintenance therapy after ASCT in '\n",
      "                                          'patients with MM with a '\n",
      "                                          'quality-of-life assessment : the '\n",
      "                                          'National Cancer Institute of Canada '\n",
      "                                          'Clinicals Trials Group Myeloma 10 '\n",
      "                                          'Trial .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide is an antiangiogenic '\n",
      "                                          'drug used in cancer therapy .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has shown clinical '\n",
      "                                          'antitumor activity in single-agent '\n",
      "                                          ', phase II clinical trials in '\n",
      "                                          'AIDS-related Kaposi_sarcoma , '\n",
      "                                          'glioma , multiple_myeloma '\n",
      "                                          'refractory to chemotherapy , and '\n",
      "                                          'hormone-refractory_prostate_cancer '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has been shown to block '\n",
      "                                          'the activity of angiogenic '\n",
      "                                          'substances like bFGF , VEGF and '\n",
      "                                          'interleukin_6 .'}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:11521808',\n",
      "                             'PMID:9240635',\n",
      "                             'PMID:11188934',\n",
      "                             'PMID:23297129',\n",
      "                             'PMID:19399582'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0000153',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:11521808',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11521808',\n",
      "                                 'value': 'Even in low TE incidence areas , '\n",
      "                                          'thalidomide combined with '\n",
      "                                          'dexamethasone was more thrombogenic '\n",
      "                                          'compared with others .'},\n",
      "                                {'name': 'PMID:9240635',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9240635',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The potential role of thalidomide '\n",
      "                                          'in the treatment of human neoplasia '\n",
      "                                          'will be confirmed by means of '\n",
      "                                          'randomized clinical trials .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'The breakthrough discovery of the '\n",
      "                                          'anti-angiogenic effects of '\n",
      "                                          'thalidomide gave impetus to a '\n",
      "                                          'series of clinical trials in '\n",
      "                                          'patients with solid tumors and '\n",
      "                                          'hematologic_malignancies .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'A randomized phase 3 trial of '\n",
      "                                          'thalidomide and prednisone as '\n",
      "                                          'maintenance therapy after ASCT in '\n",
      "                                          'patients with MM with a '\n",
      "                                          'quality-of-life assessment : the '\n",
      "                                          'National Cancer Institute of Canada '\n",
      "                                          'Clinicals Trials Group Myeloma 10 '\n",
      "                                          'Trial .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide is an antiangiogenic '\n",
      "                                          'drug used in cancer therapy .'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has shown clinical '\n",
      "                                          'antitumor activity in single-agent '\n",
      "                                          ', phase II clinical trials in '\n",
      "                                          'AIDS-related Kaposi_sarcoma , '\n",
      "                                          'glioma , multiple_myeloma '\n",
      "                                          'refractory to chemotherapy , and '\n",
      "                                          'hormone-refractory_prostate_cancer '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:11188934',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11188934',\n",
      "                                 'value': 'Thalidomide has been shown to block '\n",
      "                                          'the activity of angiogenic '\n",
      "                                          'substances like bFGF , VEGF and '\n",
      "                                          'interleukin_6 .'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:11521808',\n",
      "                             'PMID:9240635',\n",
      "                             'PMID:11188934',\n",
      "                             'PMID:23297129',\n",
      "                             'PMID:19399582'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0011830',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9480143',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9480143',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7049116',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7049116',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:4952377',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4952377',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18305057',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18305057',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18490197',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18490197',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:9480143',\n",
      "                             'PMID:7049116',\n",
      "                             'PMID:4952377',\n",
      "                             'PMID:18305057',\n",
      "                             'PMID:18490197'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0002597',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:9480143',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9480143',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:7049116',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7049116',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:4952377',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/4952377',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18305057',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18305057',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18490197',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18490197',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:9480143',\n",
      "                             'PMID:7049116',\n",
      "                             'PMID:4952377',\n",
      "                             'PMID:18305057',\n",
      "                             'PMID:18490197'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0025015',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18525436',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18525436',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:14535581',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14535581',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19322189',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19322189',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:18525436',\n",
      "                             'PMID:18624684',\n",
      "                             'PMID:14535581',\n",
      "                             'PMID:19322189',\n",
      "                             'PMID:15148528'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0011354',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18525436',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18525436',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:14535581',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14535581',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19322189',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19322189',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:18525436',\n",
      "                             'PMID:18624684',\n",
      "                             'PMID:14535581',\n",
      "                             'PMID:19322189',\n",
      "                             'PMID:15148528'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0011276',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18525436',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18525436',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:18624684',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18624684',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:14535581',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14535581',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:19322189',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19322189',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'Thalidomide is being investigated '\n",
      "                                          'for treatment of '\n",
      "                                          'renal_cell_carcinoma , and liver '\n",
      "                                          'and thyroid_cancers .'},\n",
      "                                {'name': 'PMID:15148528',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15148528',\n",
      "                                 'value': 'This review focuses on thalidomide '\n",
      "                                          \"'s mechanisms of action , \"\n",
      "                                          'biochemistry , pharmacokinetics and '\n",
      "                                          'its use in '\n",
      "                                          'erythema_nodosum_leprosum as well '\n",
      "                                          'as multiple_myeloma , graft versus '\n",
      "                                          'host_disease , and '\n",
      "                                          'renal_cell_carcinoma .'}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:18525436',\n",
      "                             'PMID:18624684',\n",
      "                             'PMID:14535581',\n",
      "                             'PMID:19322189',\n",
      "                             'PMID:15148528'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0011121',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:19830855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19830855',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Cancer cells were treated with '\n",
      "                                          'TIR-203 at various concentrations '\n",
      "                                          '-LRB- 0-10 M -RRB- and the cell '\n",
      "                                          'viability was measured using the '\n",
      "                                          'MTS assay .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In MM cells , TIR-203 effectively '\n",
      "                                          'inhibited the chymotrypsin-like '\n",
      "                                          '-LRB- CT-L -RRB- , caspase-like '\n",
      "                                          '-LRB- C-L -RRB- , and trypsin-like '\n",
      "                                          '-LRB- T-L -RRB- activities of the '\n",
      "                                          'proteasome .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'RESULTS : TIR-203 inhibited the '\n",
      "                                          'cell proliferation of MM and NB '\n",
      "                                          'cells in a dose-dependent manner at '\n",
      "                                          'significantly lower concentrations '\n",
      "                                          'than SylA .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'MATERIALS AND METHODS : TIR-203 was '\n",
      "                                          'tested against human MM and '\n",
      "                                          'neuroblastoma -LRB- NB -RRB- cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In NB cells , TIR-203 inhibited the '\n",
      "                                          'CT-L and C-L activities , but not '\n",
      "                                          'the T-L activity .'},\n",
      "                                {'name': 'PMID:20022634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20022634',\n",
      "                                 'value': 'Recently , many reports have '\n",
      "                                          'revealed that the PIK3CA gene which '\n",
      "                                          'encodes the p110 catalytic subunit '\n",
      "                                          'of PI3K kinase is mutated in many '\n",
      "                                          'human malignancies .'},\n",
      "                                {'name': 'PMID:15459912',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15459912',\n",
      "                                 'value': 'Proteins exhibiting a significant '\n",
      "                                          'increase in abundance with '\n",
      "                                          'increasing qMab included molecular '\n",
      "                                          'chaperones known to interact '\n",
      "                                          'directly with nascent '\n",
      "                                          'immunoglobulins during their '\n",
      "                                          'folding and assembly -LRB- e.g. , '\n",
      "                                          'BiP , endoplasmin , '\n",
      "                                          'protein_disulfide_isomerase -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17516591',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17516591',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:19830855',\n",
      "                             'PMID:22196580',\n",
      "                             'PMID:20022634',\n",
      "                             'PMID:15459912',\n",
      "                             'PMID:17516591'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0000008',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:19830855',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/19830855',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Cancer cells were treated with '\n",
      "                                          'TIR-203 at various concentrations '\n",
      "                                          '-LRB- 0-10 M -RRB- and the cell '\n",
      "                                          'viability was measured using the '\n",
      "                                          'MTS assay .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Variation in markers of '\n",
      "                                          'osteoblastic activation -LRB- such '\n",
      "                                          'as ALP -RRB- have also predicted '\n",
      "                                          'response and response duration in '\n",
      "                                          'patients with myeloma treated with '\n",
      "                                          'bortezomib -LRB- P < 0.0001 -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Response to bortezomib and '\n",
      "                                          'activation of osteoblasts in '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is a first-in-class '\n",
      "                                          'proteasome inhibitor developed as '\n",
      "                                          'an antineoplastic agent with marked '\n",
      "                                          'activity in relapsed/refractory MM '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'OBJECTIVE : Proteasome inhibitors '\n",
      "                                          'belong to an important class of '\n",
      "                                          'anticancer agents and bortezomib '\n",
      "                                          '-LRB- Velcade -LRB- -RRB- -RRB- has '\n",
      "                                          'been Food and Drug '\n",
      "                                          'Administration-approved for the '\n",
      "                                          'treatment of multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- and mantle_cell_lymphoma '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib is active in patients '\n",
      "                                          'with relapsed MM , including '\n",
      "                                          'elderly patients .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'This phase 1/2 trial in 60 '\n",
      "                                          'untreated MM patients aged at least '\n",
      "                                          '65 years -LRB- half older than 75 '\n",
      "                                          'years -RRB- was designed to '\n",
      "                                          'determine dosing , safety , and '\n",
      "                                          'efficacy of bortezomib plus MP '\n",
      "                                          '-LRB- VMP -RRB- .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'Bortezomib plus melphalan and '\n",
      "                                          'prednisone in elderly untreated '\n",
      "                                          'patients with multiple_myeloma : '\n",
      "                                          'results of a multicenter phase 1/2 '\n",
      "                                          'study .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In MM cells , TIR-203 effectively '\n",
      "                                          'inhibited the chymotrypsin-like '\n",
      "                                          '-LRB- CT-L -RRB- , caspase-like '\n",
      "                                          '-LRB- C-L -RRB- , and trypsin-like '\n",
      "                                          '-LRB- T-L -RRB- activities of the '\n",
      "                                          'proteasome .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'RESULTS : TIR-203 inhibited the '\n",
      "                                          'cell proliferation of MM and NB '\n",
      "                                          'cells in a dose-dependent manner at '\n",
      "                                          'significantly lower concentrations '\n",
      "                                          'than SylA .'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'MATERIALS AND METHODS : TIR-203 was '\n",
      "                                          'tested against human MM and '\n",
      "                                          'neuroblastoma -LRB- NB -RRB- cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:22196580',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22196580',\n",
      "                                 'value': 'In NB cells , TIR-203 inhibited the '\n",
      "                                          'CT-L and C-L activities , but not '\n",
      "                                          'the T-L activity .'},\n",
      "                                {'name': 'PMID:20022634',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20022634',\n",
      "                                 'value': 'Recently , many reports have '\n",
      "                                          'revealed that the PIK3CA gene which '\n",
      "                                          'encodes the p110 catalytic subunit '\n",
      "                                          'of PI3K kinase is mutated in many '\n",
      "                                          'human malignancies .'},\n",
      "                                {'name': 'PMID:15459912',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15459912',\n",
      "                                 'value': 'Proteins exhibiting a significant '\n",
      "                                          'increase in abundance with '\n",
      "                                          'increasing qMab included molecular '\n",
      "                                          'chaperones known to interact '\n",
      "                                          'directly with nascent '\n",
      "                                          'immunoglobulins during their '\n",
      "                                          'folding and assembly -LRB- e.g. , '\n",
      "                                          'BiP , endoplasmin , '\n",
      "                                          'protein_disulfide_isomerase -RRB- '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17516591',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17516591',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:19830855',\n",
      "                             'PMID:22196580',\n",
      "                             'PMID:20022634',\n",
      "                             'PMID:15459912',\n",
      "                             'PMID:17516591'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0008373',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:20460638',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20460638',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'In the present study , we have used '\n",
      "                                          'a pair of sequence-specific primers '\n",
      "                                          'in reverse transcription-polymerase '\n",
      "                                          'chain reaction -LRB- RT-PCR -RRB- '\n",
      "                                          'and sequence analysis to '\n",
      "                                          'demonstrate that the X-linked gene '\n",
      "                                          'encoding SPAN-Xb is expressed in '\n",
      "                                          'multiple_myeloma and other '\n",
      "                                          'hematologic_malignancies such as '\n",
      "                                          'chronic_lymphocytic_leukemia -LRB- '\n",
      "                                          'CLL -RRB- , '\n",
      "                                          'chronic_myeloid_leukemia -LRB- CML '\n",
      "                                          '-RRB- , and acute_myeloid_leukemia '\n",
      "                                          '-LRB- AML -RRB- .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Gene expression and immunologic '\n",
      "                                          'consequence of SPAN-Xb in myeloma '\n",
      "                                          'and other hematologic_malignancies '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Our results provide the first '\n",
      "                                          'evidence showing the role of '\n",
      "                                          'promoter methylation in the primary '\n",
      "                                          'regulation of SPAN-Xb and the '\n",
      "                                          'ability of IL-7 and GM-CSF to '\n",
      "                                          'further enhance SPAN-Xb gene and '\n",
      "                                          'protein expression in myeloma cells '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'SPAN-Xb expression in myeloma cells '\n",
      "                                          'is dependent on promoter '\n",
      "                                          'hypomethylation and can be '\n",
      "                                          'upregulated pharmacologically .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'SPAN-Xb is a novel cancer-testis '\n",
      "                                          'antigen in multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'In this study , we determined the '\n",
      "                                          'mechanisms regulating SPAN-Xb '\n",
      "                                          'expression in MM .'},\n",
      "                                {'name': 'PMID:12393489',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12393489',\n",
      "                                 'value': 'Both IL-7 and GM-CSF were also able '\n",
      "                                          'to upregulate the expression of '\n",
      "                                          'SPAN-Xb in myeloma cells , but only '\n",
      "                                          'after the promoter sequence has '\n",
      "                                          'been hypomethylated .'},\n",
      "                                {'name': 'PMID:16187275',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'Tumor cells were treated with '\n",
      "                                          '5-azacytidine and a panel of '\n",
      "                                          'cytokines were used to determine '\n",
      "                                          'their ability to induce SPAN-Xb '\n",
      "                                          'expression .'},\n",
      "                                {'name': 'PMID:16187275',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/16187275',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'name': 'PMID:20108890',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'The type I melanoma antigen gene '\n",
      "                                          '-LRB- MAGE -RRB- proteins CT7 -LRB- '\n",
      "                                          'MAGE-C1 -RRB- and MAGE-A3 are '\n",
      "                                          'commonly expressed in '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- , '\n",
      "                                          'and their expression correlates '\n",
      "                                          'with increased plasma cell '\n",
      "                                          'proliferation and poor clinical '\n",
      "                                          'outcome .'},\n",
      "                                {'name': 'PMID:20108890',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'Cellular immune responses against '\n",
      "                                          'CT7 -LRB- MAGE-C1 -RRB- and humoral '\n",
      "                                          'responses against other '\n",
      "                                          'cancer-testis antigens in '\n",
      "                                          'multiple_myeloma patients .'},\n",
      "                                {'name': 'PMID:20108890',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20108890',\n",
      "                                 'value': 'CT7 and MAGE-A3 are promising '\n",
      "                                          'antigenic targets for therapeutic '\n",
      "                                          'tumor vaccines in myeloma ; '\n",
      "                                          'therefore , it is critical to '\n",
      "                                          'determine if they are immunogenic '\n",
      "                                          'in MM patients .'},\n",
      "                                {'name': 'PMID:10916472',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10916472',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:20460638',\n",
      "                             'PMID:12393489',\n",
      "                             'PMID:16187275',\n",
      "                             'PMID:20108890',\n",
      "                             'PMID:10916472'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0000078',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:1525326',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/1525326',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:2941196',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/2941196',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8681032',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8681032',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8620298',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8620298',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:8440074',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440074',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:1525326',\n",
      "                             'PMID:2941196',\n",
      "                             'PMID:8681032',\n",
      "                             'PMID:8620298',\n",
      "                             'PMID:8440074'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0012649',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:18922293',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18922293',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:15288860',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15288860',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11843289',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11843289',\n",
      "                                 'value': 'To the best of our knowledge , CD55 '\n",
      "                                          '- or CD59-deficient red cells have '\n",
      "                                          'not been detected in '\n",
      "                                          'plasma_cell_dyscrasias -LRB- PCDs '\n",
      "                                          '-RRB- .'},\n",
      "                                {'name': 'PMID:14077037',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/14077037',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:1609190',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/1609190',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:18922293',\n",
      "                             'PMID:15288860',\n",
      "                             'PMID:11843289',\n",
      "                             'PMID:14077037',\n",
      "                             'PMID:1609190'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0011842',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:15288860',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/15288860',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:20682368',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20682368',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:3097809',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/3097809',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:21343556',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'This cohort study aimed to '\n",
      "                                          'calculate the incidence of and '\n",
      "                                          'identify the risk factors for ONJ '\n",
      "                                          'in patients with cancer treated '\n",
      "                                          'with intravenous zoledronate , '\n",
      "                                          'ibandronate , and pamidronate .'},\n",
      "                                {'name': 'PMID:21343556',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Randomized , double-blind study of '\n",
      "                                          'denosumab versus zoledronic_acid in '\n",
      "                                          'the treatment of bone metastases in '\n",
      "                                          'patients with advanced_cancer -LRB- '\n",
      "                                          'excluding '\n",
      "                                          'breast_and_prostate_cancer -RRB- or '\n",
      "                                          'multiple myeloma .'},\n",
      "                                {'name': 'PMID:21343556',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'PURPOSE : This study compared '\n",
      "                                          'denosumab , a fully human '\n",
      "                                          'monoclonal anti-receptor activator '\n",
      "                                          'of nuclear factor kappa-B ligand '\n",
      "                                          'antibody , with zoledronic_acid '\n",
      "                                          '-LRB- ZA -RRB- for delaying or '\n",
      "                                          'preventing skeletal-related events '\n",
      "                                          '-LRB- SRE -RRB- in patients with '\n",
      "                                          'advanced_cancer and bone metastases '\n",
      "                                          '-LRB- excluding breast and prostate '\n",
      "                                          '-RRB- or myeloma .'},\n",
      "                                {'name': 'PMID:21343556',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/21343556',\n",
      "                                 'value': 'Acute-phase reactions after the '\n",
      "                                          'first dose occurred more frequently '\n",
      "                                          'with ZA , as did renal adverse '\n",
      "                                          'events and elevations in serum '\n",
      "                                          'creatinine based on National Cancer '\n",
      "                                          'Institute Common Toxicity Criteria '\n",
      "                                          'for Adverse Events grading .'},\n",
      "                                {'name': 'PMID:17766137',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17766137',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': \"['biolink.phenotype_get_disease']\",\n",
      "            'publications': ['PMID:15288860',\n",
      "                             'PMID:20682368',\n",
      "                             'PMID:3097809',\n",
      "                             'PMID:21343556',\n",
      "                             'PMID:17766137'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0012639',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:8020433',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'SPAN-Xb is a novel cancer-testis '\n",
      "                                          'antigen in multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'name': 'PMID:8020433',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'As a result of the content of '\n",
      "                                          'benzene in various streams of '\n",
      "                                          'refinery products , including '\n",
      "                                          'gasoline , it is not surprising '\n",
      "                                          'that over the years studies and '\n",
      "                                          'case reports have linked gasoline '\n",
      "                                          'exposure to lymphopoietic_cancers '\n",
      "                                          '-LRB- LPC -RRB- , particularly '\n",
      "                                          'leukemia and multiple_myeloma -LRB- '\n",
      "                                          'MM -RRB- .'},\n",
      "                                {'name': 'PMID:8020433',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8020433',\n",
      "                                 'value': 'Other diseases of particular '\n",
      "                                          'interest in relation to gasoline '\n",
      "                                          'exposure are kidney_cancer , '\n",
      "                                          'malignant_melanoma , and '\n",
      "                                          'heart_disease .'},\n",
      "                                {'name': 'PMID:10835535',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/10835535',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:11333408',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/11333408',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:9345329',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9345329',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:12731663',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/12731663',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:8020433',\n",
      "                             'PMID:10835535',\n",
      "                             'PMID:11333408',\n",
      "                             'PMID:9345329',\n",
      "                             'PMID:12731663'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0030680',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.8093606487732907,\n",
      "            'edge_attributes': [{'name': 'PMID:20141670',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/20141670',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:18490254',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18490254',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'The potential role of thalidomide '\n",
      "                                          'in the treatment of human neoplasia '\n",
      "                                          'will be confirmed by means of '\n",
      "                                          'randomized clinical trials .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'The breakthrough discovery of the '\n",
      "                                          'anti-angiogenic effects of '\n",
      "                                          'thalidomide gave impetus to a '\n",
      "                                          'series of clinical trials in '\n",
      "                                          'patients with solid tumors and '\n",
      "                                          'hematologic_malignancies .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'A randomized phase 3 trial of '\n",
      "                                          'thalidomide and prednisone as '\n",
      "                                          'maintenance therapy after ASCT in '\n",
      "                                          'patients with MM with a '\n",
      "                                          'quality-of-life assessment : the '\n",
      "                                          'National Cancer Institute of Canada '\n",
      "                                          'Clinicals Trials Group Myeloma 10 '\n",
      "                                          'Trial .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Thalidomide is an antiangiogenic '\n",
      "                                          'drug used in cancer therapy .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'BACKGROUND : A 60-year-old woman '\n",
      "                                          'with multiple_myeloma relapsed '\n",
      "                                          'after a good partial response to '\n",
      "                                          'high-dose chemotherapy -LRB- '\n",
      "                                          'melphalan 200 mg/m -LRB- 2 -RRB- '\n",
      "                                          '-RRB- and autologous stem-cell '\n",
      "                                          'transplantation , followed by '\n",
      "                                          'thalidomide and prednisolone '\n",
      "                                          'maintenance therapy .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'BACKGROUND : Thalidomide is '\n",
      "                                          'effective in approximately 30 % of '\n",
      "                                          'patients with refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'We investigated the combination of '\n",
      "                                          'thalidomide with dexamethasone as '\n",
      "                                          'salvage treatment for heavily '\n",
      "                                          'pretreated patients with '\n",
      "                                          'multiple_myeloma , in order to '\n",
      "                                          'assess its efficacy and toxicity .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'CONCLUSION : The combination of '\n",
      "                                          'thalidomide with dexamethasone '\n",
      "                                          'appears active in patients with '\n",
      "                                          'refractory multiple_myeloma .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Phase II and pharmacokinetic study '\n",
      "                                          'of thalidomide in Japanese patients '\n",
      "                                          'with relapsed/refractory '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Low-dose thalidomide was an '\n",
      "                                          'effective and tolerable treatment '\n",
      "                                          'for Japanese patients with '\n",
      "                                          'relapsed/refractory myeloma .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'To obtain approval from the '\n",
      "                                          'Ministry of Health , Labor and '\n",
      "                                          'Welfare of Japan , a phase II study '\n",
      "                                          'was conducted to assess the '\n",
      "                                          'pharmacokinetics and '\n",
      "                                          'pharmacodynamics of thalidomide '\n",
      "                                          'along with its efficacy and safety '\n",
      "                                          'in Japanese patients with '\n",
      "                                          'multiple_myeloma .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'PURPOSE : We studied the efficacy '\n",
      "                                          'and safety of bortezomib -LRB- BOR '\n",
      "                                          '-RRB- for treatment of '\n",
      "                                          'multiple_myeloma in comparison with '\n",
      "                                          'thalidomide -LRB- THAL -RRB- by '\n",
      "                                          'reference to adverse events , and '\n",
      "                                          'searched for laboratory markers '\n",
      "                                          'that could be used for '\n",
      "                                          'prognostication of patients .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Clinical assessment of bortezomib '\n",
      "                                          'for multiple_myeloma in comparison '\n",
      "                                          'with thalidomide .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'BACKGROUND : After the tragic '\n",
      "                                          'events in the early 1960s , '\n",
      "                                          'thalidomide has re-emerged as '\n",
      "                                          'therapeutic for multiple_myeloma '\n",
      "                                          '-LRB- MM -RRB- .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Thalidomide has shown great promise '\n",
      "                                          'in advanced or refractory '\n",
      "                                          'multiple_myeloma either alone or in '\n",
      "                                          'combination with other agents .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'We reported arterial thrombosis in '\n",
      "                                          'two cases with multiple_myeloma '\n",
      "                                          'implemented in thalidomide '\n",
      "                                          'treatment .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Low incidence of thromboembolism in '\n",
      "                                          'relapsed/refractory myeloma '\n",
      "                                          'patients treated with thalidomide '\n",
      "                                          'without thromboprophylaxis in '\n",
      "                                          'Taiwan .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'We aimed to elucidate the TE '\n",
      "                                          'frequency in MM patients in Taiwan '\n",
      "                                          'who were treated with thalidomide '\n",
      "                                          'without TE prophylaxis .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Immunomodulatory agents , e.g. , '\n",
      "                                          'thalidomide , have expanded the '\n",
      "                                          'therapeutic options for treating '\n",
      "                                          'myeloma ; however , Western '\n",
      "                                          'countries report a high incidence '\n",
      "                                          'of thrombosis in '\n",
      "                                          'thalidomide-treated MM patients who '\n",
      "                                          'lack thromboprophylaxis .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'We retrospectively collected the '\n",
      "                                          'records of MM patients who had used '\n",
      "                                          'thalidomide from a single institute '\n",
      "                                          'between 2004 and 2010 , combined '\n",
      "                                          'these records with two other '\n",
      "                                          'Taiwanese studies , and compared '\n",
      "                                          'all three with the Korean trial .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'In relapsed/refractory myeloma '\n",
      "                                          'patients , the VTE frequency was '\n",
      "                                          'slightly lower compared with '\n",
      "                                          'Western patients irrespective of '\n",
      "                                          'treatment with thalidomide alone or '\n",
      "                                          'combined with dexamethasone .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Thalidomide , lenalidomide and '\n",
      "                                          'bortezomib have all been shown to '\n",
      "                                          'be highly effective in '\n",
      "                                          'multiple_myeloma , and '\n",
      "                                          'JAK2-inhibitors have entered phase '\n",
      "                                          'II studies of patients with '\n",
      "                                          'JAK2-positive primary myelofibrosis '\n",
      "                                          'and related diseases .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'In the thrombosis cohort , four '\n",
      "                                          'patients -LRB- 80 % -RRB- were '\n",
      "                                          'treated with thalidomide plus '\n",
      "                                          'dexamethasone .'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'In conclusion , this side effect of '\n",
      "                                          'the use of thalidomide should be '\n",
      "                                          'taken into consideration while '\n",
      "                                          'doing examinations with respect to '\n",
      "                                          'the etiology in arterial '\n",
      "                                          'thromboembolism and because of this '\n",
      "                                          'vascular complication that '\n",
      "                                          'threatens life ; we suggest '\n",
      "                                          'stopping the thalidomide treatment '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:17514361',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/17514361',\n",
      "                                 'value': 'Even in low TE incidence areas , '\n",
      "                                          'thalidomide combined with '\n",
      "                                          'dexamethasone was more thrombogenic '\n",
      "                                          'compared with others .'},\n",
      "                                {'name': 'PMID:22706703',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'A Korean trial reported low TE '\n",
      "                                          'incidence in thalidomide-treated '\n",
      "                                          'myeloma patients -LRB- 39 % were '\n",
      "                                          'given aspirin prophylactically '\n",
      "                                          '-RRB- .'},\n",
      "                                {'name': 'PMID:22706703',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/22706703',\n",
      "                                 'value': 'Of the patients in the '\n",
      "                                          'relapsed/refractory cohort -LRB- n '\n",
      "                                          '= 114 -RRB- who were given '\n",
      "                                          'thalidomide alone , none -LRB- 0/52 '\n",
      "                                          '-RRB- developed venous_TE -LRB- VTE '\n",
      "                                          '-RRB- ; however , two patients '\n",
      "                                          '-LRB- 2/35 , 5.7 % -RRB- who were '\n",
      "                                          'given thalidomide-dexamethasone as '\n",
      "                                          'a salvage treatment developed VTE '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:18490252',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/18490252',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:20141670',\n",
      "                             'PMID:18490254',\n",
      "                             'PMID:17514361',\n",
      "                             'PMID:22706703',\n",
      "                             'PMID:18490252'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0001977',\n",
      "            'type': 'has_phenotype'},\n",
      "           {'confidence': 0.739736952659432,\n",
      "            'edge_attributes': [{'name': 'PMID:8440338',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440338',\n",
      "                                 'value': 'We studied IL-3 in 7 patients with '\n",
      "                                          'markedly delayed engraftment after '\n",
      "                                          'autologous bone marrow '\n",
      "                                          'transplantation -LRB- ABMT -RRB- '\n",
      "                                          'for hematologic_malignancies -LRB- '\n",
      "                                          'acute_myeloid_leukemia 4 , '\n",
      "                                          'chronic_myeloid_leukemia 1 , '\n",
      "                                          \"myeloma 1 , non-Hodgkin 's _ \"\n",
      "                                          'lymphoma 1 -RRB- .'},\n",
      "                                {'name': 'PMID:8440338',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/8440338',\n",
      "                                 'value': 'Interleukin-3 followed by GM-CSF '\n",
      "                                          'for delayed engraftment after '\n",
      "                                          'autologous bone marrow '\n",
      "                                          'transplantation .'},\n",
      "                                {'name': 'PMID:7605999',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7605999',\n",
      "                                 'value': 'In patients with advanced '\n",
      "                                          'multiple_myeloma -LRB- MM -RRB- '\n",
      "                                          'there is an excess of production of '\n",
      "                                          'interleukin-6 -LRB- IL-6 -RRB- in '\n",
      "                                          'vivo , and elevated serum levels '\n",
      "                                          'are associated with plasmablastic '\n",
      "                                          'proliferative activity and short '\n",
      "                                          'survival .'},\n",
      "                                {'name': 'PMID:7605999',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7605999',\n",
      "                                 'value': 'These data show that anti-IL-6 MoAb '\n",
      "                                          'can suppress the proliferation of '\n",
      "                                          'myeloma cells and underscore the '\n",
      "                                          'biologic role of IL-6 for myeloma '\n",
      "                                          'growth in vivo .'},\n",
      "                                {'name': 'PMID:7605999',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/7605999',\n",
      "                                 'value': 'Furthermore , suppression of CRP '\n",
      "                                          'and worsening of '\n",
      "                                          'neutropenia/thrombocytopenia both '\n",
      "                                          'indicate that IL-6 is critically '\n",
      "                                          'involved in acute-phase responses '\n",
      "                                          'and granulopoiesis/thrombopoiesis '\n",
      "                                          '.'},\n",
      "                                {'name': 'PMID:9818705',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/9818705',\n",
      "                                 'value': ''},\n",
      "                                {'name': 'PMID:6159812',\n",
      "                                 'type': 'pubmed_article',\n",
      "                                 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/6159812',\n",
      "                                 'value': ''}],\n",
      "            'provided_by': 'biolink.phenotype_get_disease',\n",
      "            'publications': ['PMID:8440338',\n",
      "                             'PMID:7605999',\n",
      "                             'PMID:9818705',\n",
      "                             'PMID:6159812'],\n",
      "            'source_id': 'MONDO:0009693',\n",
      "            'target_id': 'HP:0004370',\n",
      "            'type': 'has_phenotype'}],\n",
      " 'nodes': [{'description': 'Abnormal reproductive system morphology',\n",
      "            'id': 'HP:0012243',\n",
      "            'name': 'Abnormal reproductive system morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the skin',\n",
      "            'id': 'HP:0000951',\n",
      "            'name': 'Abnormality of the skin',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Constitutional symptom',\n",
      "            'id': 'HP:0025142',\n",
      "            'name': 'Constitutional symptom',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal platelet count',\n",
      "            'id': 'HP:0011873',\n",
      "            'name': 'Abnormal platelet count',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Nausea and vomiting',\n",
      "            'id': 'HP:0002017',\n",
      "            'name': 'Nausea and vomiting',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of nitrogen compound homeostasis',\n",
      "            'id': 'HP:0004364',\n",
      "            'name': 'Abnormality of nitrogen compound homeostasis',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the nasal skeleton',\n",
      "            'id': 'HP:0010937',\n",
      "            'name': 'Abnormality of the nasal skeleton',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Ebola hemorrhagic fever',\n",
      "            'id': 'MONDO:0005737',\n",
      "            'name': 'Ebola hemorrhagic fever',\n",
      "            'type': ['disease']},\n",
      "           {'description': 'Abnormality of the nasal bone',\n",
      "            'id': 'HP:0010939',\n",
      "            'name': 'Abnormality of the nasal bone',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Inflammatory abnormality of the skin',\n",
      "            'id': 'HP:0011123',\n",
      "            'name': 'Inflammatory abnormality of the skin',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of urine homeostasis',\n",
      "            'id': 'HP:0003110',\n",
      "            'name': 'Abnormality of urine homeostasis',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the liver',\n",
      "            'id': 'HP:0001392',\n",
      "            'name': 'Abnormality of the liver',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal platelet morphology',\n",
      "            'id': 'HP:0011875',\n",
      "            'name': 'Abnormal platelet morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Chest pain',\n",
      "            'id': 'HP:0100749',\n",
      "            'name': 'Chest pain',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the kidney',\n",
      "            'id': 'HP:0000077',\n",
      "            'name': 'Abnormality of the kidney',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal eye morphology',\n",
      "            'id': 'HP:0012372',\n",
      "            'name': 'Abnormal eye morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Leukopenia',\n",
      "            'id': 'HP:0001882',\n",
      "            'name': 'Leukopenia',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of nervous system physiology',\n",
      "            'id': 'HP:0012638',\n",
      "            'name': 'Abnormality of nervous system physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the gingiva',\n",
      "            'id': 'HP:0000168',\n",
      "            'name': 'Abnormality of the gingiva',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the urinary system',\n",
      "            'id': 'HP:0000079',\n",
      "            'name': 'Abnormality of the urinary system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of higher mental function',\n",
      "            'id': 'HP:0011446',\n",
      "            'name': 'Abnormality of higher mental function',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the gastrointestinal tract',\n",
      "            'id': 'HP:0011024',\n",
      "            'name': 'Abnormality of the gastrointestinal tract',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Thrombocytopenia',\n",
      "            'id': 'HP:0001873',\n",
      "            'name': 'Thrombocytopenia',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of facial skeleton',\n",
      "            'id': 'HP:0011821',\n",
      "            'name': 'Abnormality of facial skeleton',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Gastrointestinal hemorrhage',\n",
      "            'id': 'HP:0002239',\n",
      "            'name': 'Gastrointestinal hemorrhage',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the digestive system',\n",
      "            'id': 'HP:0025031',\n",
      "            'name': 'Abnormality of the digestive system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Epistaxis',\n",
      "            'id': 'HP:0000421',\n",
      "            'name': 'Epistaxis',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Fever',\n",
      "            'id': 'HP:0001945',\n",
      "            'name': 'Fever',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'All',\n",
      "            'id': 'HP:0000001',\n",
      "            'name': 'All',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal axial skeleton morphology',\n",
      "            'id': 'HP:0009121',\n",
      "            'name': 'Abnormal axial skeleton morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of head or neck',\n",
      "            'id': 'HP:0000152',\n",
      "            'name': 'Abnormality of head or neck',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Morphological abnormality of the central nervous '\n",
      "                           'system',\n",
      "            'id': 'HP:0002011',\n",
      "            'name': 'Morphological abnormality of the central nervous system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of skin physiology',\n",
      "            'id': 'HP:0011122',\n",
      "            'name': 'Abnormality of skin physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Internal hemorrhage',\n",
      "            'id': 'HP:0011029',\n",
      "            'name': 'Internal hemorrhage',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal lung morphology',\n",
      "            'id': 'HP:0002088',\n",
      "            'name': 'Abnormal lung morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Fatigue',\n",
      "            'id': 'HP:0012378',\n",
      "            'name': 'Fatigue',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the integument',\n",
      "            'id': 'HP:0001574',\n",
      "            'name': 'Abnormality of the integument',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal inflammatory response',\n",
      "            'id': 'HP:0012647',\n",
      "            'name': 'Abnormal inflammatory response',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal renal physiology',\n",
      "            'id': 'HP:0012211',\n",
      "            'name': 'Abnormal renal physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the oral cavity',\n",
      "            'id': 'HP:0000163',\n",
      "            'name': 'Abnormality of the oral cavity',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal nasal morphology',\n",
      "            'id': 'HP:0005105',\n",
      "            'name': 'Abnormal nasal morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal liver morphology',\n",
      "            'id': 'HP:0410042',\n",
      "            'name': 'Abnormal liver morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of immune system physiology',\n",
      "            'id': 'HP:0010978',\n",
      "            'name': 'Abnormality of immune system physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Headache',\n",
      "            'id': 'HP:0002315',\n",
      "            'name': 'Headache',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Renal insufficiency',\n",
      "            'id': 'HP:0000083',\n",
      "            'name': 'Renal insufficiency',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the genitourinary system',\n",
      "            'id': 'HP:0000119',\n",
      "            'name': 'Abnormality of the genitourinary system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Immunodeficiency',\n",
      "            'id': 'HP:0002721',\n",
      "            'name': 'Immunodeficiency',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Reduced consciousness/confusion',\n",
      "            'id': 'HP:0004372',\n",
      "            'name': 'Reduced consciousness/confusion',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the female genitalia',\n",
      "            'id': 'HP:0010460',\n",
      "            'name': 'Abnormality of the female genitalia',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abdominal symptom',\n",
      "            'id': 'HP:0011458',\n",
      "            'name': 'Abdominal symptom',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the musculature',\n",
      "            'id': 'HP:0003011',\n",
      "            'name': 'Abnormality of the musculature',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal facial shape',\n",
      "            'id': 'HP:0001999',\n",
      "            'name': 'Abnormal facial shape',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the respiratory system',\n",
      "            'id': 'HP:0002086',\n",
      "            'name': 'Abnormality of the respiratory system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Functional abnormality of the gastrointestinal '\n",
      "                           'tract',\n",
      "            'id': 'HP:0012719',\n",
      "            'name': 'Functional abnormality of the gastrointestinal tract',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal respiratory epithelium morphology',\n",
      "            'id': 'HP:0012253',\n",
      "            'name': 'Abnormal respiratory epithelium morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Subcutaneous hemorrhage',\n",
      "            'id': 'HP:0001933',\n",
      "            'name': 'Subcutaneous hemorrhage',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of digestive system physiology',\n",
      "            'id': 'HP:0025032',\n",
      "            'name': 'Abnormality of digestive system physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Stomatitis',\n",
      "            'id': 'HP:0010280',\n",
      "            'name': 'Stomatitis',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal respiratory system morphology',\n",
      "            'id': 'HP:0012252',\n",
      "            'name': 'Abnormal respiratory system morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal thrombocyte morphology',\n",
      "            'id': 'HP:0001872',\n",
      "            'name': 'Abnormal thrombocyte morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal endocrine morphology',\n",
      "            'id': 'HP:0031071',\n",
      "            'name': 'Abnormal endocrine morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Functional respiratory abnormality',\n",
      "            'id': 'HP:0002795',\n",
      "            'name': 'Functional respiratory abnormality',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Arthralgia',\n",
      "            'id': 'HP:0002829',\n",
      "            'name': 'Arthralgia',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the upper urinary tract',\n",
      "            'id': 'HP:0010935',\n",
      "            'name': 'Abnormality of the upper urinary tract',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Localized skin lesion',\n",
      "            'id': 'HP:0011355',\n",
      "            'name': 'Localized skin lesion',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Respiratory tract infection',\n",
      "            'id': 'HP:0011947',\n",
      "            'name': 'Respiratory tract infection',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'CNS infection',\n",
      "            'id': 'HP:0011450',\n",
      "            'name': 'CNS infection',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Muscle weakness',\n",
      "            'id': 'HP:0001324',\n",
      "            'name': 'Muscle weakness',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the cardiovascular system',\n",
      "            'id': 'HP:0001626',\n",
      "            'name': 'Abnormality of the cardiovascular system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the menstrual cycle',\n",
      "            'id': 'HP:0000140',\n",
      "            'name': 'Abnormality of the menstrual cycle',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal endocrine physiology',\n",
      "            'id': 'HP:0031072',\n",
      "            'name': 'Abnormal endocrine physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Diarrhea',\n",
      "            'id': 'HP:0002014',\n",
      "            'name': 'Diarrhea',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of muscle physiology',\n",
      "            'id': 'HP:0011804',\n",
      "            'name': 'Abnormality of muscle physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the urinary system physiology',\n",
      "            'id': 'HP:0011277',\n",
      "            'name': 'Abnormality of the urinary system physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal globe morphology',\n",
      "            'id': 'HP:0012374',\n",
      "            'name': 'Abnormal globe morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Metrorrhagia',\n",
      "            'id': 'HP:0100608',\n",
      "            'name': 'Metrorrhagia',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Pain',\n",
      "            'id': 'HP:0012531',\n",
      "            'name': 'Pain',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal bleeding',\n",
      "            'id': 'HP:0001892',\n",
      "            'name': 'Abnormal bleeding',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal female reproductive system physiology',\n",
      "            'id': 'HP:0030012',\n",
      "            'name': 'Abnormal female reproductive system physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of reproductive system physiology',\n",
      "            'id': 'HP:0000080',\n",
      "            'name': 'Abnormality of reproductive system physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the coagulation cascade',\n",
      "            'id': 'HP:0003256',\n",
      "            'name': 'Abnormality of the coagulation cascade',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Skin rash',\n",
      "            'id': 'HP:0000988',\n",
      "            'name': 'Skin rash',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Sepsis',\n",
      "            'id': 'HP:0100806',\n",
      "            'name': 'Sepsis',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'multiple myeloma',\n",
      "            'id': 'MONDO:0009693',\n",
      "            'name': 'multiple myeloma',\n",
      "            'type': ['disease']},\n",
      "           {'description': 'Increased inflammatory response',\n",
      "            'id': 'HP:0012649',\n",
      "            'name': 'Increased inflammatory response',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Proteinuria',\n",
      "            'id': 'HP:0000093',\n",
      "            'name': 'Proteinuria',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of skin morphology',\n",
      "            'id': 'HP:0011121',\n",
      "            'name': 'Abnormality of skin morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the abdominal organs',\n",
      "            'id': 'HP:0002012',\n",
      "            'name': 'Abnormality of the abdominal organs',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of movement',\n",
      "            'id': 'HP:0100022',\n",
      "            'name': 'Abnormality of movement',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the skull',\n",
      "            'id': 'HP:0000929',\n",
      "            'name': 'Abnormality of the skull',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of female internal genitalia',\n",
      "            'id': 'HP:0000008',\n",
      "            'name': 'Abnormality of female internal genitalia',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of oral mucosa',\n",
      "            'id': 'HP:0011830',\n",
      "            'name': 'Abnormality of oral mucosa',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of coagulation',\n",
      "            'id': 'HP:0001928',\n",
      "            'name': 'Abnormality of coagulation',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the mouth',\n",
      "            'id': 'HP:0000153',\n",
      "            'name': 'Abnormality of the mouth',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of skeletal morphology',\n",
      "            'id': 'HP:0011842',\n",
      "            'name': 'Abnormality of skeletal morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the genital system',\n",
      "            'id': 'HP:0000078',\n",
      "            'name': 'Abnormality of the genital system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Puberty and gonadal disorders',\n",
      "            'id': 'HP:0008373',\n",
      "            'name': 'Puberty and gonadal disorders',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the skeletal system',\n",
      "            'id': 'HP:0000924',\n",
      "            'name': 'Abnormality of the skeletal system',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of cardiovascular system morphology',\n",
      "            'id': 'HP:0030680',\n",
      "            'name': 'Abnormality of cardiovascular system morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal vascular morphology',\n",
      "            'id': 'HP:0025015',\n",
      "            'name': 'Abnormal vascular morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Generalized abnormality of skin',\n",
      "            'id': 'HP:0011354',\n",
      "            'name': 'Generalized abnormality of skin',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of the vasculature',\n",
      "            'id': 'HP:0002597',\n",
      "            'name': 'Abnormality of the vasculature',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of cardiovascular system physiology',\n",
      "            'id': 'HP:0011025',\n",
      "            'name': 'Abnormality of cardiovascular system physiology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Vascular skin abnormality',\n",
      "            'id': 'HP:0011276',\n",
      "            'name': 'Vascular skin abnormality',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of blood circulation',\n",
      "            'id': 'HP:0011028',\n",
      "            'name': 'Abnormality of blood circulation',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal homeostasis',\n",
      "            'id': 'HP:0012337',\n",
      "            'name': 'Abnormal homeostasis',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of temperature regulation',\n",
      "            'id': 'HP:0004370',\n",
      "            'name': 'Abnormality of temperature regulation',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormality of nervous system morphology',\n",
      "            'id': 'HP:0012639',\n",
      "            'name': 'Abnormality of nervous system morphology',\n",
      "            'type': ['phenotypic_feature']},\n",
      "           {'description': 'Abnormal thrombosis',\n",
      "            'id': 'HP:0001977',\n",
      "            'name': 'Abnormal thrombosis',\n",
      "            'type': ['phenotypic_feature']}]}\n"
     ]
    }
   ],
   "source": [
    "from pprint import pprint\n",
    "\n",
    "pprint(KG)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
